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The coronavirus spike protein is a critical determinant of cell tropism and 
pathogenicity.  It is expressed on the viral surface and is responsible for binding the 
host cell receptor and initiating fusion of the viral and host cell membranes.  The work 
presented herein is an investigation into the genetic and biochemical properties of 
spike that influence the in vivo pathogenesis of feline and canine coronaviruses.  A 
targeted sequencing approach was undertaken to identify mutations in a key viral 
activation site that correlate with the development of systemic disease after feline 
coronavirus infection.  A similar strategy was used to characterize the spike proteins 
of canine coronaviruses associated with fatal enteritis in dogs and a thorough 
histopathologic characterization was performed in an attempt to independently 
confirm reports pantropic canine coronavirus variants.  
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CHAPTER ONE 
 
Introduction to Feline and Canine Coronaviruses 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Licitra BN, Duhamel GE, Whittaker GR.  2014.  Canine enteric coronaviruses: 
emerging pathogens with distinct recombinant spike proteins.  Viruses 6:3363-76. 
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1.1 Why Study Coronaviruses? 
Severe Acute Respiratory Syndrome (SARS), which emerged in 2002, and Middle 
East Respiratory Syndrome (MERS), which emerged in 2012 (1, 2) are two dramatic 
examples of coronaviruses’ remarkable ability to jump between host species.  Both 
viruses have ancestral reservoirs in bats and have infected other mammals on their 
paths to emergence in humans (3, 4).  Coronavirus emergence and evolution is 
influenced by mutation and recombination events that occur against the background of 
their huge RNA genomes.  How coronaviruses evolve to infect new host species is an 
area of active research.   
The aim of this work is to identify changes in the coronavirus genome that are 
associated with the ability to enter new cell types.  It focuses on feline and canine 
coronaviruses, two closely related pathogens of cats and dogs that primarily cause 
intestinal disease.  Feline coronavirus (FCoV) is well known for its ability to escape 
the intestinal tract and infect monocytes and macrophages.  The ability of the virus to 
infect these cells is associated with fatal, immune-mediated disease.  Canine enteric 
coronavirus (CCoV) is less well studied; however, systemic fatal infections have been 
reported.  The work presented here provides insights into a mechanism of tropism 
switching that all coronaviruses – not just FCoV and CCoV – have the potential to 
employ.   
1.2 Coronavirus Structure and Genotyping 
Coronaviruses are enveloped, single-stranded, (+)-sense RNA viruses that infect 
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humans and a wide variety of animal species (5, 6).  They are primarily pathogens of 
the gastrointestinal tract.  Coronavirus particles are composed of four major structural 
proteins; spike (S), envelope (E), membrane (M), and nucleocapsid (N) (7). The 
association of the N protein with the genomic RNA forms the helical nucleocapsid that 
is surrounded by an icosahedral structure composed of the viral M protein. The virus 
enters cells upon receptor binding and membrane fusion mediated by the S protein (8).  
Like many other (+)-sense RNA viruses, it replicates within the cytoplasm in 
association with a complex membranous network known as a viral factory (9). 
Coronaviruses employ a unique mechanism of replication. The (+) strand RNA viral 
genome is transcribed into a full-length (−) strand RNA genomic template and (−) 
strand subgenomic templates for mRNA synthesis. RNA recombination is believed to 
occur during this process of (−) strand RNA synthesis. Subsequently, the (−) strand 
templates are transcribed to form the (+) strand RNA genomes and (+) strand nested 
subgenomic mRNAs (10).  While 3'-exonuclease activity allows some degree of 
proofreading (11), the coronavirus genome is highly prone to mutation during 
replication. During virus assembly, the virion buds into the endoplasmic reticulum-
Golgi intermediate compartment (ERGIC) where it enters the secretory pathway of the 
cell, allowing maturation and processing of the heavily glycosylated viral spike 
protein. The virus exits the cell via exocytosis.  
Coronaviruses are phylogenetically divided into several genera, termed alpha, beta, 
and gamma (12).  The existence of a fourth genus – deltacoronavirus – has also been 
suggested (13).  Classification of coronaviruses into different genera is based in part 
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on the presence or absence of small open-reading frames situated downstream of the 
genes encoding the main structural proteins.  
1.3 Spike (S) Structure and Function 
Spike is the most variable protein in the coronavirus genome.  It varies in length from 
1100 amino acids in infectious bronchitis virus (IBV) to 1400 amino acids in FCoV.  
It is expressed as a homotrimer on the surface of viral particles (Figure 1.1).  Spike 
consists of two protein subunits, designated S1 and S2. The S1 subunit interacts with 
host-cell receptors and attachment factors.  It makes up the highly exposed globular 
head of the S protein and is under intense selective pressure from host antibodies.  The 
S2 domain is responsible for fusion of the viral and host-cell membranes (14, 15).   It 
is highly conserved among coronaviruses and makes up the stalk region of the protein.  
In some coronaviruses, the boundary of the S1 and S2 subunits contains a pattern of 
amino acids, or motif, that is recognized by host proteases and is referred to as the 
S1/S2 cleavage site (16, 17).  A second cleavage motif is located slightly downstream 
and is termed S2’ (18).  The S2’ cleavage motif is present in all coronaviruses and 
cleavage at this site likely required to expose the viral fusion peptide and initiate the 
infection process.   
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Figure 1.11 This representation shows the trimeric (inset) and monomeric forms of the 
coronavirus spike protein and is based on the three-dimensional predicted model found 
in the PDB database (PDB entry 1T7G, (19)). The S1 and S2 domains as well as the 
cleavage sites and putative fusion peptide are highlighted.  
     
    
 
 
 
                                                
1 Adapted from S. Belouzard, Millet, J.K., Licitra, B.N. and Whittaker, G.R. Mechanisms of Coronavirus Cell Entry Mediated 
by the Viral Spike Protein. Viruses 2012, 4, 1011-1033; doi:10.3390/v4061011 
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immunodominant neutralizing domain (the 5B19 epitope) on the MHV S2 subunit [108]. While a 
crystal structure of the SARS-CoV S ectodomain has not yet be solved, a predictive model of the 
quaternary structure is available: PDB entry 1T7G [109]. In the context of this model, the novel S2 
fusion peptide is mainly helical (especially the conserved residues SxIEDLLF), with a short central 
unstructured region, and is in a relatively exposed position mid-way down the trimeric spike protein 
complex (Figure 3). This structure and position within the S trimer is consistent with its function as a 
viral fusion peptide. Comparisons with other fusion proteins reveal some similarities to the “internal” 
fusion peptides of Ebola virus and avian leukosis virus. Like these viruses, the coronavirus fusion 
peptide is exposed by proteolytic cleavage [6,89,110], yet is not a classic “external” fusion peptide like 
influenza HA. 
Figure 3. SARS-CoV spike protein three-dimensional predicted structure. This representation, 
shows the trimeric (inset) a  monomeric f rms of the protein and is based on the  
three-dimensional predicted model found in the PDB database (PDB entry 1T7G, [109]). 
Note that the predicted model does not include residues 681-736 of the protein. The S1 and 
S2 domains as well as the cleavage sites and putative fusion peptide are highlighted. 
 
6. Conclusions 
In the past ten years, many new coronaviruses have been identified. They infect a wide range of 
hosts from mammals to birds. Closely related coronaviruses have been identified in distantly related 
animals suggesting recent interspecies jumps. Coronavirus diversity is fundamentally due to the low 
fidelity of the virally encoded RNA-dependent-RNA-polymerase that generates around 10í3 to 10í5 
substitutions per site per year. The large size and replication strategy of the coronavirus genome also 
allows for frequent homologous recombination, a process that enables exchange of genetic material 
during co-infection. Persistent infection leads to the accumulation of adaptive mutations. The 
consequences of coronavirus species barrier jumping can be devastating and result in severe disease 
and mortality, as exemplified by the SARS outbreak. The spike protein is the major determinant of 
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Receptor Binding  
Infection of the host cell is initiated when S binds to the extracellular domain of 
specific membrane-bound receptors on the host cell surface. Coronaviruses take 
advantage of host aminopeptidase-N (APN), angiotensin converting enzyme-2 (ACE-
2), dipeptidyl peptidase-4 (DPP4), carcinoembryonic antigen-related cell adhesion 
molecule 1 (CEACAM1), heparin sulfate, sialic acid, and calcium dependent (C-type) 
lectins to gain entry into the host cell (Table 1.1) Coronaviruses’ ability to interact 
with a variety of host proteins and sugars helps them to infect a diverse range of 
mammalian and avian species.   
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Table 1.1 Coronavirus genera, species, and host receptor usage  
Genus Species Receptor, co-receptor 
 
 
Alphacoronavirus 
- Alphacoronavirus-1 comprising: 
    FCoV-1 
    CCoV-1 
    FCoV-2 
    CCoV-2 
    TGEV 
    Porcine Respiratory Coronavirus 
(PRCoV) 
-  Human coronavirus 229E   
-  Human coronavirus NL63   
-  Porcine Epidemic Diarrhea Virus 
(PEDV)  
 
 
unknown (20), DC-SIGN  (21)  
unknown 
APN (22), DC-SIGN (21, 23)  
APN (24) 
APN (22), sialic acid (25)  
APN (26) 
APN (22) 
ACE2 (27) 
APN? (28) (29) 
 
 
 
Betacoronavirus 
- Betacoronavirus-1 comprising: 
    Bovine coronavirus (BCoV)   
    Human coronavirus OC43 (HCoV-
OC43)   
    Equine coronavirus (ECoV)   
    Canine respiratory coronavirus 
(CRCoV) 
- Mouse hepatitis virus (MHV)  
- Human SARS-CoV  
- Human MERS-CoV 
 
sialic acid (30) 
sialic acid (30)  
presumed to be sialic acid 
presumed to be sialic acid 
CEACAM1(31)  
ACE2 (32), DC/L-SIGN (33) 
DPP4 (34) 
 
Gammacoronavirus 
- Avian coronavirus comprising:  
    Infectious Bronchitis Virus (IBV) 
    Pheasant coronavirus 
    Turkey coronavirus 
 
sialic acid (35), DC/L-SIGN 
(36) 
presumed to be sialic acid 
presumed to be sialic acid 
 
 
Deltacoronavirus 
- Bulbul coronavirus HKU11  
- Thrush coronavirus HKU12  
unknown 
 
APN = aminopeptidase N, ACE2 = angiotensin converting enzyme 2, CEACAM1 = carcinoembryonic 
antigen-related cell adhesion molecule 1, DPP4 = dipeptidyl peptidase-4, DC-SIGN = dendritic cell-
specific intercellular adhesion molecule-3-grabbing non-integrin, L-SIGN = liver/lymph node-specific 
intercellular adhesion molecule-3-grabbing integrin 
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Membrane Fusion   
S is a class 1 fusion protein that behaves similarly to influenza virus hemagglutinin 
(HA), retrovirus envelope (Env) and paramyxovirus fusion (F) (37, 38). Fusion must 
be tightly regulated in order to target the virus to permissive cell types and reduce the 
number of abortive infections.  Class 1 fusion proteins are primed for fusion by 
proteolytic cleavage, and activated by receptor binding, low pH, or a combination of 
the two (39).  This sequence of events is required to destabilize the S protein, 
triggering conformational changes that result in exposure of a string of hydrophobic 
amino acids known as the fusion peptide.  The fusion peptide inserts into the closely 
opposed host cell membrane.  At this point, heptad repeats within the S2 domain form 
coiled-coil structures that draw the viral and host membranes into direct opposition 
and allow the creation of a fusion pore through which viral genome enters the host 
cytoplasm (8, 40, 41).  
Fusion occurs either at the cell surface, or after endocytosis of the viral particle. For 
many coronaviruses, it is still unclear which point of entry is used.  Recent evidence 
suggests that coronaviruses have the ability to utilize either pathway dependent on 
their proteolytic priming and pH activation.  For example, SARS-CoV enters the host 
cell via endocytosis and cathepsin L-mediated spike protein cleavage (42); however if 
this pathway is blocked, the virus can enter via trypsin or elastase-mediated cleavage 
at the cell surface (43).  
Modification of fusion requirements is one way in which viruses acquire the ability to 
infect new cell types.  For example, Mouse Hepatitis Virus (MHV) strain JHM does 
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not need to bind its receptor in order to initiate fusion.  This infection strategy is 
termed receptor-independent spread.  S proteins on virons budding from infected cells 
trigger fusion of adjacent host cell membranes, leading to propagation of the virus via 
syncytia formation.  MHV-JHM’s enhanced fusogenicity is the result of an unstable S 
protein, an adaptation that carries the fitness cost of indiscriminate fusion and abortive 
infection, but may confer an advantage during the process of adaptation to a new host 
(44).  
Cleavage Activation 
The coronavirus spike protein is activated by proteolytic cleavage at one or two 
cleavage sites (S1/S2 and S2’) (10).  In other virus systems, notably Influenza A and 
Newcastle Disease, amino acid substitutions at similar sites can result in changes in 
viral virulence and pathogenicity (39).  Depending on the individual coronavirus, 
cleavage at S1/S2 may or may not occur (8).  S2’ cleavage is likely a more universal 
requirement, and is linked directly to exposure of the viral fusion peptide (14, 18, 29). 
Cleavage at the two sites can occur via the action of a wide range of proteases, e.g., 
trypsin or trypsin-like proteases, cathepsins, elastase, or furin (45). 
Cleavage may occur at one or more points in the coronavirus life cycle.  The first 
opportunity is in the progenitor cell during viral egress through the trans-Golgi 
network where furin may cleave multi-basic amino acid motifs located at the boundary 
of the S1 and S2 subunits. In vivo, the cleaved S1 and S2 subunits remain tenuously 
associated by hydrogen bonds.  Cleavage at the S1/S2 site is dispensable, but when 
present, is thought to result in destabilization of spike and increased fusogenicity.  
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Viruses that lack a S1/S2 furin motif are released from the host cell in an uncleaved 
state.  The S2’ cleavage site lies about 100 amino acids downstream of S1/S2, 
immediately proceeding the hydrophobic viral fusion peptide.  Regardless of whether 
or not cleavage occurs at S1/S2, cleavage at S2’ is likely required for infection.  
Cleavage at this position frees the buried fusion peptide so it can insert into the host 
cell membrane.  Since this event is linked directly to fusion, it is not generally initiated 
until the virus binds its receptor.  Target-cell proteases such as cathepsins B and L are 
known to cleave the S2’ site (18, 46).  Modification of viral proteolytic cleavage 
motifs - either by amino acid substitutions or post-transcriptional modifications such 
as glycosylation - has the potential to modulate S fusogenicity and infectivity.  
1.4 Introduction to Feline Coronavirus (FCoV) 
 
FCoV is a pathogen of both wild and domestic cats.  It is endemic in multi-cat 
environments such as catteries and shelters (47).  All cats that are exposed to FCoV 
develop mild or sub-clinical enteritis; however a small subset of infected animals will 
progress to a systemic, invariably fatal immune-mediated disease.  This dichotomy in 
clinical signs (mild enteritis versus fatal immune mediated organ failure) led to the 
classification of FCoVs into two biotypes: feline enteric coronavirus (FECV) and 
feline infectious peritonitis virus (FIPV).  The term biotype refers to the virus 
associated with one of two clinical outcomes:  FECVs cause mild self-limiting 
enteritis while FIPVs cause systemic disease and death.  The majority of the scientific 
evidence suggests that FIPVs arise from FECVs by mutation(s) that occur 
spontaneously within each affected cat.  The immune response of the cat plays an 
  11 
important role in determining whether FIPVs will arise and if so, whether they spread 
systemically via activated monocytes and macrophages. 
1.5 FCoV Pathogenesis and Clinical Signs 
 
Feline enteric coronavirus (FECV) 
FECV replicates within the intestinal epithelium.  Most cats are asymptomatic, but 
some present with fever, anorexia and mild diarrhea (48, 49). This form of FCoV is 
ubiquitous among cats in multi-cat environments such as catteries and shelters.  
Monocyte-associated viremia is common (50-52), but productive infection of these 
cells is abortive and is not sustained longer than 24 hours (53).  Virus is shed in the 
feces and is transmitted by the fecal-oral route.  Primary infection lasts several months 
and virus shedding is highest at this time, particularly among kittens.  A subset of cats 
clear the virus, but most continue to shed at low levels for up to two years (48, 54).  
Colonic columnar epithelial are thought to serve as a reservoir for persistent infection 
and shedding (49, 52).  Immunity is not long lasting and re-infection is common (55).  
The virus can survive up to seven weeks in cold, dry conditions and can be transmitted 
by fomites such as clothing and brushes (56).   
Feline infectious peritonitis virus (FIPV) 
In 1-5% of FECV infections (48), the virus gains the ability to replicate efficiently 
within blood monocytes and tissue macrophages.  The key difference between FECV 
and FIPV is that FIPV initiates productive infection of monocytes, leading to their 
activation.  Feline infectious peritonitis (FIP) is a monocyte-triggered disease that 
involves generalized activation of monocytes, macrophages, and endothelial cells.  
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The characteristic lesion of FIP is granulomatous phlebitis (57). FIPV infection of 
susceptible feline monocytes triggers up-regulation of mitogen-activated protein 
kinase (MAPK) leading to the production of the pro-inflammatory cytokines tumor 
necrosis factor (TNF)-α and interleukin (IL)-1β (58).  Enhanced expression of the 
adhesion molecules CD18 and CD11a facilitates emigration of FIPV-infected 
monocytes into tissues, resulting in the formation of granulomatous lesions (57, 59).  
Monocyte and macrophage derived vascular endothelial growth factor (VEGF) and 
matrix metalloproteinases (MMPs) are suspected to play roles in the increased 
vascular permeability that characterizes FIP (57, 60).   
The individual immune responses play an important role in determining which cats 
develop FIP.  The monocytes of some cats are refractory to infection with both 
biotypes of FCoV (53).  Resistance is associated with the development of an IFN-γ 
driven cellular immune response (61, 62).  In susceptible cats, productive infection of 
monocytes and macrophages triggers a TNF- α response that quickly becomes 
dysregulated (58, 61, 63).  The outcome is immune mediated tissue destruction, organ 
failure, and death (64).   
Clinical signs are initially non-specific and include fever, lethargy, anorexia, and 
weight loss.  Laboratory tests often reveal a non-regenerative anemia, neutrophilia 
with a left shift, plus a profound lymphopenia due to cytokine mediated depletion of 
CD8+ and CD4+ T-cells (65-67).   Hyperbilirubinemia and elevated serum aspartate 
aminotransferase (AST) are also common findings (68).  In cats that mount a 
predominantly Th2-mediated humoral immune response, the disease is characterized 
by the development of a protein rich effusion within the body cavities (69).  This form 
  13 
of the disease is known as effusive, or wet FIP, and it progresses rapidly.  The time 
from diagnosis to death can be as short as a few days.  This is due in part to a 
phenomenon known as antibody-dependent enhancement in which antibodies against 
FIP serve to opsonize the virus and allow it to enter monocytes and macrophages by a 
specialized receptor that recognizes antibodies attached to invading pathogens.  (70, 
71).  This receptor is called Fc after the region of the antibody it binds – the so called 
fragment crystalizible.  Uptake via this pathway actually leads to enhancement of 
infection and the development of more fulminant disease (72).  Less commonly, cats 
will present with the non-effusive, or dry form of FIP.  This form of the disease is 
associated with a mixed Th1/Th2 response that prolongs the clinical course of 
infection, but is ineffective in clearing the virus (73). Antibody, antigen complexes 
may appear as white keratic precipitates on the surface of the cornea.  Uveitis, which 
is defined as inflammation of the pigmented structures of the eye, may manifest as a 
darkening of the iris and abnormal pupil shape.  Virus mediated inflammation centered 
around the ventricles in the brain results in neurological signs including ataxia, 
tremors, and/or seizures (74).  The course of dry FIP is more protracted and cats may 
live for months before eventually succumbing to the disease.  
FIP has a predilection for kittens and young cats (75).  It often strikes more than one 
animal in a household and has been known to devastate shelters and catteries.  Age, 
overcrowding, feline leukemia virus (FeLV) co-infection, and genetic predisposition 
are known risk factors for the development of FIP (64).   
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There are two proposed theories regarding the origin of FIP.  The first, and most 
widely supported, is the internal mutation hypothesis (76, 77).  In this paradigm, every 
case of FIP arises uniquely from mutation of FECV within the affected cat.  An 
important supposition of the internal mutation hypothesis is FIP is not readily 
transmissible, making infection of monocytes an evolutionary dead-end for the virus.  
The second theory on the origin of FIP is the circulating strain hypothesis (78, 79).  It 
states that both FECV and FIPV are actively circulating among cats.  Whether or not 
an animal develops FIP depends upon which circulating variant it is exposed to.  This 
theory has the advantage of explaining how outbreaks of FIP - which are commonly 
encountered by breeders and shelter veterinarians - might occur.  The internal 
mutation and circulating strain hypotheses need not be mutually exclusive.  It is 
entirely plausible that some strains of FECV are more likely to transition to FIPV than 
others.  Increasing lines of evidence suggest that multiple mutations are associated 
with the transition from FECV to FIPV.  For example, changes in the viral accessory 
genes 3c and the structural protein spike both correlate with the development of FIP 
(80, 81).  If a given FECV strain already possesses one or more of the predisposing 
mutations, then the switch to FIPV is increasingly likely.  This hypothesis, while 
attractive, remains untested.   
1.6 FCoV Diagnosis 
Primary differential diagnoses for effusive FIP include heart disease, neoplasia, and 
cholangiohepatitis.  Non-effusive cases of FIP are more challenging to diagnose, 
especially when ocular and neurological signs are absent.  Several informative tests 
can be run on serum or effusion including total protein, albumin/globulin ratio, γ-
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globulin, coronavirus antibody titer, and coronavirus specific RT-PCR (82). The gold 
standard for FIP diagnosis remains tissue biopsy followed by immunohistochemistry 
revealing granulomatous lesions that contain coronavirus antigen (Figure 1.2).  
 
 
Figure 1.2 Photomicrograph of omentum from a case of FIP.  Coronavirus antigen is 
present within pyogranulomas and stains red in this immunohistochemistry assay.  
Image provided by ANTECH diagnostics and used with permission.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.7  FCoV Serotypes 
Two serotypes of FCoV are circulating in cats.  They can be differentiated by the 
antigenic and genetic properties of their spike protein (83).  Feline coronavirus type 1 
(FCoV-1) is more prevalent clinically but grows poorly in cell culture and is therefore 
understudied when compared to feline coronavirus type 2 (FCoV-2), which is easily 
propagated in vitro but accounts for less than 10% of clinical cases (84). FCoV-2 is 
the result of homologous recombination and displays a spike protein that is most 
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similar to CCoV-2 (85).  Both FCoV-1 and FCoV-2 infection can result in clinical 
signs of FECV or FIPV.  The terms serotype and biotype are distinct in meaning: 
serotypes are defined by the genetic and antigenic properties of the virus (FCoV-1 vs 
FCoV-2), while biotypes are defined by clinical outcome (FECV vs FIPV).  
FCoV-1  
The prototype FCoV-1 viruses include FIPV TN406 (more commonly known as 
FIPV-Black) and FECV Rogers-Morris (FECV-RM) (86, 87).  FECV-RM does not 
replicate in cell culture and is propagated through fecal-oral transmission in laboratory 
cats.  Like FECV-RM, most FCoV-1 viruses cannot be isolated in tissue culture.  It 
has been hypothesized that this is due to the requirement of a receptor or co-receptor 
that is not expressed on cultured cells (20).  The FCoV-1 host cell receptor is 
unknown.  FIPV-Black was isolated in the early 1980’s and grows well in feline AKD 
(lung) and CrFK (kidney) cell lines.  FIPV-Black is pathogenic to cats in its low-
passage form, but has reduced virulence after tissue culture adaptation (88). 
Circulating FCoV-1 viruses can be sequenced from the feces of cats living in multi-cat 
environments as well as from the tissues of cats diagnosed with FIP (89).  
FCoV-2 
The prototype FCoV-2 viruses include FIPV WSU-79-1146 and FECV WSU-79-
1683, both of which were isolated in 1979 (90).  Type 2 FCoVs use the receptor 
aminopeptidase N (fAPN) (22).  They display a CCoV spike protein (85) and have the 
ability to infect canine as well as feline cell lines.  Efficient replication in feline 
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macrophages is limited to FIPV-1146 (91).  In vivo, 1146 is the most virulent of all 
FIPV isolates, while FECV-1683 causes inapparent enteritis (48).  
Receptor Binding  
Aminopeptidase N (APN) has been identified as the receptor for many 
Alphacoronaviruses, including FCoV-2, CCoV-2, TGEV, and human coronavirus 
(HCoV)-229E (22). FCoV-1 has been suggested to use a different, yet unidentified 
receptor (20).  The dendritic cell specific ICAM-3-grabbing non-integrin (DC-SIGN) 
expressed on dendritic cells, macrophages, and monocytes has been shown function as 
a co-receptor for both type 1 and type 2 FCoVs (21, 23).  Sialic acid binding is 
essential for the enterotropism of closely related TGEV (25, 92), but its role in FCoV 
enterotropism remains unstudied. 
 
Membrane Fusion 
Fusion occurs either at the cell surface, or after endocytosis of the viral particle. For 
FCoVs, it is still unclear which point of entry is used.  The dependence of FECV-1683 
on endosomal cathepsins and low pH suggests that it enters through the endosomal 
pathway while the pH and cathepsin L independence of FIPV-1146 suggests that it 
may fuse directly at the cell surface (46).  
Priming by Proteolytic Cleavage  
FCoV-1 spike has an unusual feature for Alphacoronaviruses, the presence of a furin-
like cleavage motif at the S1/S2 boundary (16) (Figure 1.3).  Furin is a serine protease 
that belongs to a family of enzymes called proprotein convertases (PCs) (93).  Along 
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with furin, six other PCs proteases, PC1, PC2, PC4, PC5, PACE4 and PC7, share the 
same multi-basic amino acid recognition motif: [R/K]-[X]-[R/K]-[R], where X is any 
amino acid and R and K are the basic amino acids arginine and lysine, respectively.  
The role of furin-like enzymes in the proteolytic priming of FCoV-1 is yet to be 
determined.     
Like most Alphacoronaviruses, FCoV-2 viruses lack a furin cleavage site.  They rely 
on cleavage by endosomal proteases such as cathepsin L and B (46).  Cathepsins are a 
group of cysteine proteases within the papain family of proteases (94).  FIPV-1146 
can be activated by cathepsin B in order to initiate infection.  In contrast, FECV-1683 
requires cathepsin B, cathepsin L, and low pH (46).  Proteolytic activation motifs are 
known pathogenicity determinants for Newcastle Diseae and Influenza A viruses.  
Amino acid mutations in proteolytic activation motifs within the coronavirus S protein 
could help explain the tropism switch from that defines the transition from FECV to 
FIPV.   
Figure 1.3 Multiple sequence alignment of the spike proteins of FCoV-1 viruses 
FECV-RM (ACT10854.1) and FIPV-Black (BAC05493.1) and FCoV-2 viruses FIPV-
1146 (AGZ84516.1) and FECV-1683 in the region of the two activation sites (S1/S2 
and S2’) and the viral fusion peptide (underlined) (14, 18). The alignment was created 
using ClustalX. Basic residues likely involved in cleavage activation are colored red, / 
indicates the putative location of cleavage.   
 
     S1/S2 furin motif            S2’cathepsin motif 
FECV-RM   785 HTQPRRSRR/STPN 973 PTIGKR/SAVEDLLF 
FIPV-Black   783 HTQAKRSRR/PTSH 969 PKIGAR/SAVEDLLF  
FECV-1683   768 WTTT--------   954 SKRKYR/SAIEDLLF 
FIPV-1146   765 WTTT--------       956 SKRK/YGSAIEDLLF    
                  fusion peptide  
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1.8 FCoV Prevention and Treatment 
 
Controlling FCoV is challenging and largely impractical due to its endemic circulation 
among communally housed cats (74).  In shelters and catteries, regular disinfection of 
litter-boxes and food bowls can help to reduce the number of infectious viral particles 
in the environment, but will not eliminate FCoV (64).  Although a vaccine is 
commercially available, the American Association of Feline Practitioners Advisory 
Board does not recommend it due to its limited efficacy.   It is a temperature sensitive 
mutant administered as an intranasal formulation (95) that provides protection against 
FCoV-2 but may not be cross-protective against the more prevalent FCoV-1 strains 
(74).  Additionally, it cannot be administered until after 16 weeks, at which point most 
kittens are already seropositive (96).  Antibody-dependent enhancement of FIP has 
made development of more effective vaccines challenging (97, 98).  Catteries seeking 
to minimize FIP are encouraged to eliminate overcrowding, actively manage litter 
boxes and litter dust, breed a minimum number of litters, and restrict breeding to 
adults that have not previously produced kittens that have died of FIP (74).  Sadly, 
there are no effective treatments for FIP.  Palliative treatment followed by euthanasia 
is the standard of care for this disease.   
 
1.9 FCoV Summary 
A combination of host, viral, and environmental factors contribute to the development 
of FIP.  Overcrowded conditions cause stress and increase the likelihood of co-
infection, both of which may result in immunosuppression and failure to control 
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coronavirus replication.  In addition, overcrowding increases the viral load in the 
environment.  Host factors such as age and genetic background also affect an animal’s 
chances of developing FIP.  Lastly, viral factors that enhance tropism for monocytes 
and macrophages are suspected to play a critical role.  Mutations in the viral proteins 
3c and S are associated with FIP, but the exact combination of viral factors required 
for the transition from FECV to FIPV remains unknown.     
1.10 Introduction to Canine Enteric Coronaviruses (CCoV) 
CCoV is a common infection of dogs, particularly those housed in large groups such 
as kennels, shelters, and breeding facilities. CCoV was first recognized as a pathogen 
of dogs following virus isolation of the prototype 1-71 virus in 1971 during an 
outbreak of gastroenteritis in military dogs (99). Classically, CCoV was considered to 
cause only self-limiting enteritis with mild diarrheal disease (100). Recently, CCoV 
has emerged as a significant pathogen in veterinary medicine, and is increasingly 
found to be an important cause of disease.   
1.11 CCoV Structure and Genotyping 
There are two known types of canine coronaviruses: CCoV is a member of the 
alphacoronavirus genus (12), and the more recently identified canine respiratory 
coronavirus (CRCoV) is a member of the betacoronavirus genus (101). CCoV is 
closely related to transmissible gastroenteritis virus (TGEV) of pigs, ferret coronavirus 
and FCoV of cats (12); whereas CRCoV is more closely related to bovine coronavirus 
(102). All enteric CCoVs (along with the related viruses of cats, pigs, and ferrets) are 
  21 
given the same strain designation (Alphacoronavirus-1) from a taxonomic perspective. 
There are two distinct serotypes of CCoV: type 1 and type 2 (103, 104). CCoV-1 and 
CCoV-2, though closely related to each other, have markedly different spike proteins 
(105) - a situation analogous to that in cats, where feline coronaviruses (FCoV) also 
exist as two equivalent serotypes (type 1 and type 2, based on antigenically distinct 
spike proteins (106). It has been proposed that type 1 CCoVs and FCoVs evolved 
from a common ancestral virus, and that the canine and feline type 2 lineages arose 
from multiple recombination events with an unidentified genetic source (107). A 
summary of the genome organization of CCoV-1 and CCoV-2 is shown in Figure 1.4.   
 
Figure 1.4 Image representation of the genomes of CCoV-1 and CCoV-2. Adapted 
from Lorusso et al. (107). 
 
 
CCoV-1 viruses were initially based on analysis of CCoVs with a variant M gene 
(108)—with Elmo/02 as the prototype strain (108, 109).  Like other CCoV’s, these 
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variant viruses can be sequenced from the feces of young dogs with diarrheal disease.  
It is now known that the major differences between viruses belonging to CCoV-1 and 
CCoV-2 are primarily found within the spike protein, and account for the distinct 
serological properties of these two viruses.  
CCoV-1 isolates are not culturable in cell culture systems.  In vivo, CCoV-1 viruses 
are thought to co-circulate extensively with CCoV-2 viruses, often occurring as co-
infections (110-115). This extensive co-circulation, combined with the capacity for 
recombination inherent in coronavirus replication, suggests that natural selection of 
novel recombinant viruses is not uncommon. Such a situation has been proposed for 
the divergent CCoV-A76 as well as other similar viruses that have CCoV-1/CCoV-2 
recombinant spike proteins (24, 116). This indicates that CCoV-1-like viruses have 
been in circulation in dogs for a considerable time prior to the identification of 
Elmo/02. 
The first identified CCoV strain 1-71, is now categorized as a type 2 virus (CCoV-2). 
Further classification of CCoV-2s into distinct subtypes (CCoV-2a, CCoV-2b) has 
been proposed, based on the sequence of the first 300 amino acids of the spike protein, 
a region known as the N-terminal domain (NTD). The NTD is an important 
determinant of intestinal tropism in closely related TGEV (25, 117). The CCoV IIa 
and IIb classifications are not officially accepted within CCoV taxonomy, but are 
widely cited in the literature. CCoV-2a viruses have a NTD consistent with the 
prototype CCoV. These viruses exist in two biotypes that differ in pathogenicity and 
tissue tropism. The “classical” CCoV-2a biotype is restricted to the small intestine, 
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where it causes enteritis. In contrast, the emergent “pantropic” CCoV-2a biotype can 
spread systemically, causing leukopenia (118-120). The viruses CB/05 and 450/07 
have been studied extensively as prototype pantropic CCoVs. (111, 119-122).  The 
second variant, CCoV-2b, is genetically distinct from CCoV-2a, with the CCoV-2b 
spike gene having a TGEV-like NTD (123, 124). Like TGEV, CCoV-2b causes 
enteritis in neonatal animals. CCoV-2b RNA has been detected by PCR assays in 
various organs outside of the intestinal tract, primarily in dogs that are co-infected 
with canine parvovirus (112, 123).  Isolate 341/05 has been proposed as a prototype 
CCoV-2b (123). 
Based on the finding of a novel NTD in A76-like viruses, we propose the creation of a 
new subgroup, CCoV-2c, which consists of CCoV type 2 viruses with a CCoV-1- or 
FCoV-1-like N-terminal domain. These viruses have been reported in both the United 
States and Sweden (24, 116). Other viruses with similar biological properties may 
have also been identified in the past, including an atypical CCoV from a breeding 
facility in 1997 (125). As CCoV-A76 has been isolated and characterized (24), this 
serves as a convenient prototype CCoV-2c. An image of the various spike protein 
domains for CCoVs, and a summary of NTD phylogeny, is shown in Figure 1.5. 
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Figure 1.5 (A) Image representation of a coronavirus spike protein. Key features are 
identified, including the N-terminal domain (NTD) and C-domain within the S1 
receptor-binding domain, and the fusion peptide, two heptad repeats (HR1 and HR2) 
and transmembrane domain (TM) in the S2 fusion domain. The two cleavage sites for 
protease activation (S1/S2 and S2’) are shown; (B) Image representation of the 
different domains present within the spike proteins of alpha-coronaviruses of cats 
(FCoV), dogs (CCoV) and pigs (TGEV). The different NTDs are color-coded to 
indicate homology and proposed recombination events across the species, with the 
remainder of S1 depicted in light gray and S2 in dark gray; (C) Phylogenetic tree of 
the NTDs present within the spike proteins of representative coronaviruses of cats 
(FCoV), dogs (CCoV) and pigs (TGEV) (The following virus sequences were used for 
alignment. NTD = aa 1-279 (based on CCoV-A76). FCoV-1 = Black (BAC05493.1); 
FCoV-2 = WSU-79-1146 (AGZ84516.1); CCoV-2a = CCoV CB/05 (AAZ91437.1); 
CCoV-2b = CCoV 341/05 (ACJ63231.1); CCoV-1 = CCoV Elmo/02 (AAP72149.1); 
CCoV-2c = CCoV-A76 (AEQ61968.1); CRCoV = CRCoV4182 (ABG78748.1); 
TGEV (CAB91145.1)). The tree was created using ClustalX [45] and FigTree 
software [46]; (D) Structural model of a coronavirus spike protein based on PDB file 
1T7G [47], in surface rendering. The NTD is colored magenta, the remainder of S1 is 
light gray and the S2 domain is colored dark gray. Two views of the trimeric spike are 
shown, a side view and a top view. 
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cAPN but not fAPN as a receptor. The relative lack of glycosylation on fAPN compared to cAPN may 
account for these differences [29]. 
Figure 2. (A) Image representation of a coronavirus spike protein. Key features  
are identified, including the N-terminal domain (NTD) and C-domain within the S1 
receptor-binding domain, and the fusion peptide, two heptad repeats (HR1 and HR2) and 
t ansmem rane domain (TM) in t S2 fusion domain. T  two cleav ge sites for protease 
activation (S1/S2 and S2’) are shown; (B) Image representation of the different domains 
present within the spike proteins of alpha-coronaviruses of cats (FCoV), dogs (CCoV) and 
pigs (TGEV). The different NTDs are color-coded to indicate homology and proposed 
recombination events across the species, with the remainder of S1 depicted in light gray 
and S2 in dark gray; (C) Phylogenetic tree of the NTDs present within the spike proteins  
of representativ  coronaviruse  of cats (FCoV), dogs (CCoV) and pigs (TGEV) (The 
following viru  sequences were u ed for alignment. NTD = aa 1-279 (based on CCoV-A76). 
FCoV-I = Black (BAC05493.1); FCoV-II = WSU-79-1146 (AGZ84516.1); CCoV-IIa = 
CCoV CB/05 (AAZ91437.1); CCoV-IIb = CCoV 341/05 (ACJ63231.1); CCoV-I = CCoV 
Elmo/02 (AAP72149.1); CCoV-IIc = CCoV-A76 (AEQ61968.1); CRCoV = CRCoV4182 
(ABG78748.1); TGEV (CAB91145.1)). The tree was created using ClustalX [45] and 
FigTree software [46]; (D) Structural model of a coronavirus spike protein based on PDB 
file 1T7G [47], in surfac  rendering. The NTD is colored magenta, the remain i
light gray and the S2 do ain is colored dark gray. T o vie s of the tri eric spike are 
shown, a side view and a top view. 
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CCoV-2 viruses (such as 1-71) typically grow readily in cell culture, with A-72 cells 
(canine tumor fibroblast cells derived from unknown tissue type) widely used for virus 
propagation. 1-71 also grows well in a variety of feline cell lines (e.g., CRFK), but, 
interestingly, not in many other canine cell lines (24). 
1.12 Functional Aspects of the CCoV S Protein 
Receptor Binding and Host Tropism 
The coronavirus spike protein is a major antigenic determinant and is also responsible 
for host cell receptor binding and viral entry (126). Aminopeptidase N (APN) has been 
shown to act as a common receptor for many alphacoronaviruses, including FCoV and 
TGEV (127). Although each virus would be assumed to utilize a species-specific 
homolog in its respective host during infection, the feline homologue (fAPN) has been 
shown to act as a common receptor for type 2 FCoV, type 2 CCoV and TGEV (22). 
This property is unlike most other coronaviruses, which have highly species-specific 
receptors. Such broad receptor-binding ability has likely played a role in the zoonotic 
transfer and genetic recombination events that have defined the evolution of animal 
alphacoronaviruses. Feline and human APN are also receptors for the human 
alphacoronavirus HCoV-229E, but not for another human alphacoronavirus, NL63 
[43,44]. Presumably, the canine APN acts as the in vivo receptor for all CCoV-2s, as 
shown for 1-71 (24). In the case of the CCoV-2c A76, the presence of a divergent 
APN-binding domain within the spike glycoprotein, the “C-domain”, has resulted in 
the ability to use cAPN but not fAPN as a receptor. The relative lack of glycosylation 
on fAPN compared to cAPN may account for these differences. 
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The receptor determinants for the serotype 1 FCoV/CCoV group are much less certain. 
While there is some evidence for fAPN as an FCoV type 1 receptor (22), other studies 
have concluded that there is a distinct receptor for FCoV type 1 (20, 128). Overall, 
receptor determinants for CCoV type 1 viruses remain essentially unknown. 
In addition to a specific proteinaceous receptor, there are indications that lectin-based 
interactions via sugar moieties, on either the virus or the host, may play a role in the 
receptor-binding complex for FCoV types 1 and 2 and TGEV (21, 23, 25, 117, 129) 
and the same situation may also apply to CCoVs. Many coronaviruses also bind sialic 
acid, which can be an important determinant of tissue tropism and pathogenesis, but 
this has not been investigated for FCoVs or CCoVs. 
Activation by Proteolytic Cleavage 
The FCoV/CCoV type 1 and 2 lineages present an interesting and distinct difference in 
spike protein cleavage-activation. The type 1 lineage shows the presence of two 
distinct protease cleavage motifs (R-R-S/A-R-R-S/A at S1/S2 and G/K-R-S at S2’), 
whereas the type 2 lineage is missing an obvious motif at S1/S2 and has a single 
distinctive R-K-R-Y/F-R-S cleavage motif at S2’. This implies that the viruses in 
these two lineages have quite distinct means of cleavage activation. A multiple 
sequence alignment summarizing these sites is shown in Figure 1.6. While mutations 
in the FCoV cleavage site have been linked to a change of cleavability by the protease 
furin (which cleaves readily at R-R-S/A-R-R-S/A motifs) and correlate with gain of 
macrophage tropism and the development of FIP in cats (130), there is currently no 
evidence for cleavage site mutations in highly pathogenic CCoV strains. 
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Figure 1.6 Multiple sequence alignment of the spike proteins of representative 
coronaviruses of cats (FCoV) dogs (CCoV and CRCoV) and pigs (TGEV) (The 
following virus sequences were used for alignment. FCoV-1 = RM (ACT10854); 
FCoV-2 = WSU-79-1683 (AFH58021.1); CCoV-2a = CCoV CB/05 (AAZ91437.1); 
CCoV-2b = CCoV 341/05 (ACJ63231.1); CCoV-1 = CCoV Elmo/02 (AAP72149.1); 
CCoV-2c = CCoV-A76 (AEQ61968.1); CRCoV = CRCoV4182 (ABG78748.1); 
TGEV (CAB91145.1).), in the region of the two activation sites (S1/S2 and S2’). The 
alignment was created using ClustalX [45]. The expected cleavage motif is in bold. 
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1.13 CCoV Pathogenesis and Clinical Presentation 
CCoV is transmitted by the fecal-oral route; however, it is unclear whether 
transmission by other routes including aerosols can occur. After ingestion, CCoV 
typically infects and replicates within the cytoplasm of mature epithelial cells along 
the sides and the tip of intestinal villi, while sparing the epithelium that lines the 
intestinal crypts (Figure 1.7). Infected villous enterocytes undergo degeneration 
characterized by shortening, distortion and loss of microvilli of the brush border, 
leading to sloughing of necrotic cells into the lumen. The loss of mature villous 
enterocytes causes atrophy of intestinal villi, which become attenuated in an attempt to 
maintain the integrity of the intestinal barrier. In response to the loss of villous 
enterocytes, there is an increase in mitotic activity of the crypt epithelium and a net 
expansion of the pool of immature enterocytes. Together, these changes in the small 
intestinal morphology translate into a loss of normal digestive and absorptive 
functions and the clinical signs of diarrhea and dehydration in affected dogs (131). 
CCoV is generally thought of as a mild, but highly contagious, enteritis of young 
dogs, most often under 12 weeks of age (100, 132, 133) In some cases, CCoV 
infection can be fatal, particularly in puppies co-infected with other pathogens such as 
canine parvovirus (134, 135). Therefore, the range of clinical signs from loose stools 
to severe watery diarrhea with high morbidity and variable mortality is mainly 
determined by the age at the onset of infection, the level and type of pathogen 
exposure, and the degree of maternal transfer of immunity. 
In recent years, an increasing number of reports of infections by highly virulent 
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CCoVs have also been documented in puppies without apparent coinfections (110, 
112, 116, 121, 136-139). In the case of the “pantropic” CCoV-2a viruses, infection 
results in a fatal multisystemic illness, with various clinical signs similar to canine 
parvovirus infection, and including high fever, hemorrhagic gastroenteritis, 
neurological signs, and lymphopenia. The most consistent clinical sign of pantropic 
CCoV-2a is leukopenia (118-120).  Most studies of pantropic CCoV-2a report the 
presence of viral RNA in various tissues, including lungs, lymph nodes, liver, spleen, 
kidneys, urinary bladder and brain. Evidence for replication of these pantropic viruses 
outside of the gastrointestinal tract is based on demonstration of CCoV antigen by 
immunohistochemical staining of lung tissue taken from a single dog (111, 122), and 
reports of virus isolation from various visceral organs (111, 118, 119). Viral isolation 
is often unsuccessful, even from tissues with the highest viral RNA levels (112, 119). 
The genetic markers for pantropic CCoV-2a’s are currently unknown. TGEV-like 
CCoV-2b has also been associated with systemic spread, but only in cases of co-
infection with canine parvovirus. Some features of systemic infection that are similar 
to severe acute respiratory syndrome (SARS) in humans and feline infectious 
peritonitis (FIP) in cats, have been documented for systemic fatal CCoV-2 infections 
(122), including pulmonary alveolar damage, fibrinous exudation and macrophage 
involvement. In spite of similarities between these viruses and frequent sub-clinical 
infections, it is clear that systemic and lethal FIP is a much more common outcome for 
FCoV infection of cats, compared to CCoV infection of dogs. 
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1.14 Emergence of CCoV Variants  
It is clear that coronaviruses have high potential for emergence of novel variants with 
altered tropism and pathogenesis. In large part this can be explained by several factors: 
a combination of recombination and mutation within the viral genome and that many 
coronaviruses exist as quasi-species, the availability of natural reservoirs for the virus 
and the “modular” nature of the viral spike protein (140). Recent studies have 
highlighted the extraordinary complexity of canine coronavirus genomics. The 
increased likelihood of high-density housing for dogs increases the viral load of 
coronavirus in the population, and increases the likelihood of novel viruses emerging 
within dogs. It is now well-established that the feline coronavirus FIPV WSU-79-1146 
arose following recombination with a canine coronavirus (85), and other recombinant 
canine-feline viruses have been identified (141). Increased co-housing of dogs with 
other species, particularly cats, also increases the chance of novel recombinant 
coronaviruses emerging across species. 
1.15 Laboratory Diagnosis 
Definitive diagnosis of CCoV-1 induced disease is currently difficult; thus, it is not 
commonly done or available. The virus can be identified by visualization of viral 
particles in stool specimens following negative staining and examination by 
transmission electron microscopy; however, this is not a routinely available diagnostic 
tool. Virus isolation can be achieved for CCoV-2, but not for CCoV-1 viruses, and 
again, this is not commonly available. The definitive test is post-mortem identification 
of viral antigen by immunofluorescence or immunohistochemical staining of tissue 
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sections (Figure 1.7). The most useful ante-mortem tests are RT-PCR-based, which 
are highly sensitive assays (110, 142, 143) A common PCR test can reliably detect 
alphacoronaviruses (51), and more specific PCR tests can be employed for further 
characterization into specific serotypes or genotypes; however, because of the highly 
variable nature of CCoV genomes, novel variants may be missed with this approach. 
Serological tests are of limited use since they can only confirm exposure to CCoV and 
cannot currently discriminate between infecting CCoV serotypes or genotypes. 
Figure 1.7 Photomicrographs of small intestine taken from a two-week-old puppy 
with typical lesions of CCoV infection. (A) Severe atrophy of intestinal villi with 
attenuated low cuboidal to squamous enterocytes (hematoxylin and eosin stain; 20× 
original magnification). (B) Coronavirus antigen is present within the cytoplasm of 
infected villous enterocytes (immunohistochemistry; 20× original magnification). 
 
1.16 Vaccination and Treatment 
A variety of inactivated and modified-live virus vaccines are commercially available 
and designed to prevent infection with CCoV (131). Current vaccines are safe, but 
provide only incomplete protection—in that they reduce, but do not eliminate, CCoV 
replication in the intestinal tract (125, 144). As these vaccines are likely based on the 
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classical CCoV-2a viruses, protection against CCoV-1 strains with these vaccines is 
unlikely, and protection against the variant type 2 strains is uncertain. Treatment of 
CCoV-1nduced gastroenteritis is mainly by supportive care, including good 
maintenance of fluid and electrolytes. There are no available anti-viral drugs for 
treatment of CCoV infections. 
  
  33 
References  
1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier 
RAM. 2012. Isolation of a Novel Coronavirus from a Man with Pneumonia in 
Saudi Arabia. New England Journal of Medicine 367:1814-1820. 
2. 2003. Weekly Epidemiological Record. World Health Organization. 
3. Alagaili AN, Briese T, Mishra N, Kapoor V, Sameroff SC, de Wit E, 
Munster VJ, Hensley LE, Zalmout IS, Kapoor A, Epstein JH, Karesh WB, 
Daszak P, Mohammed OB, Lipkin WI. 2014. Middle East Respiratory 
Syndrome Coronavirus Infection in Dromedary Camels in Saudi Arabia. mBio 
5. 
4. Song H-D, Tu C-C, Zhang G-W, Wang S-Y, Zheng K, Lei L-C, Chen Q-X, 
Gao Y-W, Zhou H-Q, Xiang H, Zheng H-J, Chern S-WW, Cheng F, Pan 
C-M, Xuan H, Chen S-J, Luo H-M, Zhou D-H, Liu Y-F, He J-F, Qin P-Z, 
Li L-H, Ren Y-Q, Liang W-J, Yu Y-D, Anderson L, Wang M, Xu R-H, 
Wu X-W, Zheng H-Y, Chen J-D, Liang G, Gao Y, Liao M, Fang L, Jiang 
L-Y, Li H, Chen F, Di B, He L-J, Lin J-Y, Tong S, Kong X, Du L, Hao P, 
Tang H, Bernini A, Yu X-J, Spiga O, Guo Z-M, Pan H-Y, He W-Z, 
Manuguerra J-C, Fontanet A, Danchin A, Niccolai N, Li Y-X, Wu C-I, 
Zhao G-P. 2005. Cross-host evolution of severe acute respiratory syndrome 
coronavirus in palm civet and human. Proceedings of the National Academy of 
Sciences of the United States of America 102:2430-2435. 
5. Lai M, Holmes K. 2001. Coronaviridae: the viruses and their replication. In 
Knipe DM, Howely PM (ed.), Fields Virology. Lippincott Wilkins and 
Williams. 
6. Pearlman S, Gallagher TM, Snijder EJ. 2008. Nidoviruses. ASM Press, 
Washington, DC. 
7. Hogue BG, Machamer CE. 2008. Coronavirus Structural Proteins and Virus 
Assembly, p. 179-200. In Pearlman S, Gallagher TM, Snijder EJ (ed.), 
Nidoviruses. ASM Press, Washington, DC. 
8. Bosch BJ, Rossen JWA, Bartelink W, Zuurveen SJ, de Haan CAM, 
Duquerroy S, Boucher CAB, Rottier PJM. 2008. Coronavirus Escape from 
Heptad Repeat 2 (HR2)-Derived Peptide Entry Inhibition as a Result of 
Mutations in the HR1 Domain of the Spike Fusion Protein. Journal of Virology 
82:2580-2585. 
9. Netherton CL, Wileman T. 2011. Virus factories, double membrane vesicles 
and viroplasm generated in animal cells. Current Opinion in Virology 1:381-
387. 
10. Masters PS, Perlman S. 2013. Coronaviridae. In Knipe DM, Howley PM 
(ed.), Fields Virology, 6 ed. Lippincott, Williams and Wilkins, Philadelphia, 
PA. 
11. Denison MR, Graham RL, Donaldson EF, Eckerle LD, Baric RS. 2011. 
Coronaviruses: An RNA proofreading machine regulates replication fidelity 
and diversity. RNA Biology 9:270-279. 
  34 
12. King AMQ. 2012. Virus taxonomy : classification and nomenclature of 
viruses : ninth report of the International Committee on Taxonomy of Viruses. 
Academic Press, London. 
13. Woo P, P. SK, Lam CSF, Y. CC, Tsang AKL, N. JH, Bai R, Teng JLL, 
Tsang CCC, Wang M, Zheng B-J, Chan K-H, Kwok-Yung, Yuen KY. 
2012. Discovery of Seven Novel Mammalian and Avian Coronaviruses in the 
Genus Deltacoronavirus Supports Bat Coronaviruses as the Gene Source of 
Alphacoronavirus and Betacoronavirus and Avian Coronaviruses as the Gene 
Source of Gammacoronavirus and Deltacoronavirus. Journal of Virology 
86:3995-4008. 
14. Madu IG, Roth SL, Belouzard S, Whittaker GR. 2009. Characterization of 
a Highly Conserved Domain within the Severe Acute Respiratory Syndrome 
Coronavirus Spike Protein S2 Domain with Characteristics of a Viral Fusion 
Peptide. Journal of Virology 83:7411-7421. 
15. Perlman S, Netland J. 2009. Coronaviruses post-SARS: Update on 
replication and pathogenesis. Nature Reviews Microbiology 7:439-450. 
16. de Haan CA, Haijema BJ, Schellen P, Wichgers Schreur P, te Lintelo E, 
Vennema H, Rottier PJ. 2008. Cleavage of group 1 coronavirus spike 
proteins: how furin cleavage is traded off against heparan sulfate binding upon 
cell culture adaptation. Journal of Virology 82:6078-6083. 
17. Yamada Y, Liu DX. 2009. Proteolytic Activation of the Spike Protein at a 
Novel RRRR/S Motif Is Implicated in Furin-Dependent Entry, Syncytium 
Formation, and Infectivity of Coronavirus Infectious Bronchitis Virus in 
Cultured Cells. Journal of Virology 83:8744-8758. 
18. Belouzard S, Chu VC, Whittaker GR. 2009. Activation of the SARS 
coronavirus spike protein via sequential proteolytic cleavage at two distinct 
sites. Proceedings of the National Academy of Science 106:5871–5876. 
19. Bernini A, Spiga O, Ciutti A, Chiellini S, Bracci L, Yan X, Zheng B, 
Huang J, He M-L, Song H-D, Hao P, Zhao G, Niccolai N. 2004. Prediction 
of quaternary assembly of SARS coronavirus peplomer. Biochemical and 
biophysical research communications 325:1210-1214. 
20. Dye C, Temperton N, Siddell SG. 2007. Type I feline coronavirus spike 
glycoprotein fails to recognize aminopeptidase N as a functional receptor on 
feline cell lines. The Journal of general virology 88:1753-1760. 
21. Regan AD, Whittaker GR. 2008. Utilization of DC-SIGN for entry of feline 
coronaviruses into host cells. Journal of Virology 82:11992-11996. 
22. Tresnan D, Levis R, Holmes KV. 1996. Feline aminopeptidase N serves as a 
receptor for feline, canine, porcine, and human coronaviruses in serogroup I. 
Journal of Virology 70:8669-8674. 
23. Regan AD, Ousterout DG, Whittaker GR. 2010. Feline Lectin Activity Is 
Critical for the Cellular Entry of Feline Infectious Peritonitis Virus. Journal of 
Virology 84:7917-7921. 
24. Regan AD, Millet JK, Tse LPV, Chillag Z, Rinaldi VD, Licitra BN, 
Dubovi EJ, Town CD, Whittaker GR. 2012. Characterization of a 
  35 
recombinant canine coronavirus with a distinct receptor-binding (S1) domain. 
Virology 430:90-99. 
25. Schultze B, Krempl C, Ballesteros ML, Shaw L, Schauer R, Enjuanes L, 
Herrler G. 1996. Transmissible gastroenteritis coronavirus, but not the related 
porcine respiratory coronavirus, has a sialic acid (N-glycolylneuraminic acid) 
binding activity. J Virol 70:5634-5637. 
26. Delmas B, J G, Sjostrom H, Noren O, Laude H. 1993. Further 
characterization of aminopeptidase-N as a receptor for coronaviruses. 
Advances Experimental Medicine Biology 342:293-298. 
27. Hofmann H, Pyrc K, van der Hoek L, Geier M, Berkhout B, Pöhlmann S. 
2005. Human coronavirus NL63 employs the severe acute respiratory 
syndrome coronavirus receptor for cellular entry. Proceedings of the National 
Academy of Science 102:7988-7993. 
28. Li BX, Ge JW, Li YJ. 2007. Porcine aminopeptidase N is a functional 
receptor for the PEDV coronavirus. Virology 365:166-172. 
29. Wicht O, Li W, Willems L, Meuleman TJ, Wubbolts RW, van Kuppeveld 
FJM, Rottier PJM, Bosch BJ. 2014. Proteolytic Activation of the Porcine 
Epidemic Diarrhea Coronavirus Spike Fusion Protein by Trypsin in Cell 
Culture. Journal of Virology 88:7952-7961. 
30. Vlasak R, Luytjes W, Spaan W, Palese P. 1988. Human and bovine 
coronaviruses recognize sialic acid-containing receptors similar to those of 
influenza C viruses. Proceedings of the National Academy of Science 85:4526-
4529. 
31. Holmes K, Boyle J, Weismiller D, Compton S, Williams R, Stephensen C, 
Frana M. 1987. Identification of a receptor for mouse hepatitis virus. 
Advances in Experimental Medical Biology 218:Advances in Experimental 
Medical Biology  
32. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran 
M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M. 2003. 
Angiotensin-converting enzyme 2 is a functional receptor for the SARS 
coronavirus. Nature 426:450-454. 
33. Marzi A, Gramberg T, Simmons G, Mo ̈ller P, Rennekamp A, Krumbiegel 
M, Geier M, Eisemann J, Turza N, Saunier B, Steinkasserer A, Becker S, 
Bates P, Hofmann H, Po ̈hlmann S. 2004. DC-SIGN and DC-SIGNR Interact 
with the Glycoprotein of Marburg Virus and the S Protein of Severe Acute 
Respiratory Syndrome Coronavirus. Journal of Virology 78:12090–12095. 
34. Raj VS, Mou H, Smits SL, Dekkers DHW, Muller MA, Dijkman R, Muth 
D, Demmers JAA, Zaki A, Fouchier RAM, Thiel V, Drosten C, Rottier 
PJM, Osterhaus ADME, Bosch BJ, Haagmans BL. 2013. Dipeptidyl 
peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. 
Nature 495:251-254. 
35. Winter C, Schwegmann-Weßels C, Cavanagh D, Neumann U, Herrler G. 
2006. Sialic acid is a receptor determinant for infection of cells by avian 
Infectious bronchitis virus. Journal of General Virology 87:1209-1216. 
  36 
36. Zhang Y, Buckles E, Whittaker GR. 2012. Expression of the C-type lectins 
DC-SIGN or L-SIGN alters host cell susceptibility for the avian coronavirus, 
infectious bronchitis virus. Veterinary Microbiology 157:285-293. 
37. Colman PM, Lawrence MC. 2003. The structural biology of type I viral 
membrane fusion. Nat Rev Mol Cell Biol 4:309-319. 
38. Earp L, Delos S, Park H, White J. 2005. The many mechanisms of viral 
membrane fusion proteins. Current Topics in Microbiology and Immunology 
285:25-66. 
39. Klenk H, Garten W. 1994. Activation cleavage of viral spike proteins by host 
proteases, p. 241–280, Cellular Receptors for Animal Viruses. Cold Spring 
Harbor Press. 
40. Duquerroy S, Vigouroux A, Rottier PJM, Rey FA, Jan Bosch B. 2005. 
Central ions and lateral asparagine/glutamine zippers stabilize the post-fusion 
hairpin conformation of the SARS coronavirus spike glycoprotein. Virology 
335:276-285. 
41. Petit CM, Melancon JM, Chouljenko VN, Colgrove R, Farzan M, Knipe 
DM, Kousoulas KG. 2005. Genetic analysis of the SARS-coronavirus spike 
glycoprotein functional domains involved in cell-surface expression and cell-
to-cell fusion. Virology 341:215-230. 
42. Huang IC, Bosch BJ, Li F, Li W, Lee KH, Ghiran S, Vasilieva N, 
Dermody TS, Harrison SC, Dormitzer PR, Farzan M, Rottier PJM, Choe 
H. 2006. SARS Coronavirus, but Not Human Coronavirus NL63, Utilizes 
Cathepsin L to Infect ACE2-expressing Cells. Journal of Biological Chemistry 
281:3198-3203. 
43. Matsuyama S, Ujike M, Morikawa S, Tashiro M, Taguchi F. 2005. 
Protease-mediated enhancement of severe acute respiratory syndrome 
coronavirus infection. Proceedings of the National Academy of Science 
102:12543-12547. 
44. Krueger DK, Kelly SM, Lewicki DN, Ruffolo R, Gallagher TM. 2001. 
Variations in Disparate Regions of the Murine Coronavirus Spike Protein 
Impact the Initiation of Membrane Fusion. Journal of Virology 75:2792-2802. 
45. Belouzard S, Millet JK, Licitra BN, Whittaker GR. 2012. Mechanisms of 
Coronavirus Cell Entry Mediated by the Viral Spike Protein. Viruses 4:1011-
1033. 
46. Regan A, Shraybman R, Cohen RD, Whittaker GR. 2008. Differential role 
for low pH and cathepsin-mediated cleavage of the viral spike protein during 
entry of serotype II feline coronaviruses. Veterinary Microbiology 132:235-
238. 
47. Pedersen N. 1976. Serologic studies of naturally occurring feline infectious 
peritonitis. American Journal Veterinary Research 37. 
48. Pedersen NC, Allen CE, Lyons LA. 2008. Pathogenesis of feline enteric 
coronavirus infection. Journal of Feline Medicine and Surgery 10:529-541. 
49. Vogel L, van der Lubben M, teLintelo E, Bekker C, Geerts T, Schuijeff 
LS, Grinwis G, Egberink H, Rottier PJ. 2010. Pathogenic characteristics of 
persistent feline entericcoronavirus infection in cats. Veterinary Research 41. 
  37 
50. Can-Şahna K, Ataseven VS, Pınar D, Oğuzoğlu TÇ. 2007. The detection of 
feline coronaviruses in blood samples from cats by mRNA RT-PCR. Journal of 
Feline Medicine and Surgery 9:369-372. 
51. Herrewegh APM, de Groot RJ, Cepica A, Egberink HF, Horzinek MC, 
Rottier PJ. 1995. Detection of feline coronavirus RNA in feces, tissues, and 
body fluids of naturally infected cats by reverse transcriptase PCR. Journal of 
Clinical Microbiology 33:684-689. 
52. Kipar A, Meli ML, Baptiste KE, Bowker LJ, Lutz H. 2010. Sites of feline 
coronavirus persistence in healthy cats. Journal of General Virology 91:1698-
1707. 
53. Dewerchin HL, Cornelissen E, Nauwynck HJ. 2005. Replication of feline 
coronaviruses in peripheral blood monocytes. Arch Virol 150:2483-2500. 
54. Foley J. 1997. Patterns of feline coronavirus infection and fecal shedding from 
cats in multiple-cat environments. Journal of the American Veterinary Medical 
Association 210:1307-1312. 
55. Addie DD, Schaap IAT, Nicolson L, Jarrett O. 2003. Persistence and 
transmission of natural type I feline coronavirus infection. Journal of General 
Virology 84:2735-2744. 
56. Kahn CMLSM, Co. 2010. The Merck veterinary manual. Merck & Co., 
Whitehouse Station, N.J. 
57. Kipar A, May H, Menger S, Weber M, Leukert W, Reinacher M. 2005. 
Morphologic Features and Development of Granulomatous Vasculitis in Feline 
Infectious Peritonitis. Veterinary Pathology Online 42:321-330. 
58. Regan AD, Cohen RD, Whittaker GR. 2009. Activation of p38 MAPK by 
feline infectious peritonitis virus regulates pro-inflammatory cytokine 
production in primary blood-derived feline mononuclear cells. Virology 
384:135-143. 
59. Olyslaegers DAJ, Dedeurwaerder A, Desmarets LMB, Vermeulen BL, 
Dewerchin HL, Nauwynck HJ. 2013. Altered expression of adhesion 
molecules on peripheral blood leukocytes in feline infectious peritonitis. 
Veterinary Microbiology 166:438-449. 
60. Takano T, Ohyama T, Kokumoto A, Satoh R, Hohdatsu T. 2011. Vascular 
endothelial growth factor (VEGF), produced by feline infectious peritonitis 
(FIP) virus-infected monocytes and macrophages, induces vascular 
permeability and effusion in cats with FIP. Virus Research 158:161-168. 
61. Kiss I, Poland AM, Pedersen NC. 2004. Disease outcome and cytokine 
responses in cats immunized with an avirulent feline infectious peritonitis virus 
(FIPV)-UCD1 and challenge-exposed with virulent FIPV-UCD8. Journal of 
Feline Medicine and Surgery 6:89-97. 
62. Hsieh L-E, Chueh LL. 2014. Identification and genotyping of feline 
infectious peritonitis-associated single nucleotide polymorphisms in the feline 
interferon-y gene. Veterinary Research 45. 
63. Kipar A, Meli ML, Failing K, Euler T, Gomes-Keller MA, Schwartz D, 
Lutz H, Reinacher M. 2006. Natural feline coronavirus infection: Differences 
  38 
in cytokine patterns in association with the outcome of infection. Veterinary 
Immunology and Immunopathology 112:141-155. 
64. Addie D, Belák S, Boucraut-Baralon C, Egberink H, Frymus T, Gruffydd-
Jones T, Hartmann K, Hosie MJ, Lloret A, Lutz H, Marsilio F, Pennisi 
MG, Radford AD, Thiry E, Truyen U, Horzinek MC. 2009. Feline 
Infectious Peritonitis: ABCD Guidelines on Prevention and Management. 
Journal of Feline Medicine and Surgery 11:594-604. 
65. de Groot-Mijnes JDF, van Dun JM, van der Most RG, de Groot RJ. 2005. 
Natural History of a Recurrent Feline Coronavirus Infection and the Role of 
Cellular Immunity in Survival and Disease. Journal of Virology 79:1035-1044. 
66. Sharif S, Arshad S, Hair-Bejo M, Omar AR, Zeenathul NA, Alazawy A. 
2010. Diagnostic methods for feline coronavirus: a review. Veterinary 
Medicine International 210. 
67. Haagmans BL, Egberink HF, Horzinek MC. 1996. Apoptosis and T-cell 
depletion during feline infectious peritonitis. Journal of Virology 70:8977-
8983. 
68. Tsai H-Y, Chueh L-L, Lin C-N, Su B-L. 2011. Clinicopathological findings 
and disease staging of feline infectious peritonitis: 51 cases from 2003 to 2009 
in Taiwan. Journal of Feline Medicine and Surgery 13:74-80. 
69. Kai K, Yukimune M, Murata T, Uzuka Y, Kanoe M, Matsumoto H. 1992. 
Humoral Immune Responses of Cats to Feline Infectious Peritonitis Virus 
Infection. Journal of Veterinary Medical Science 54:501-507. 
70. Pedersen N, Boyle J. 1980. Immunologic phenomena in the effusive form of 
feline infectious peritonitis. American Journal Veterinary Research 41:868-
876. 
71. Weiss RC, Scott FW. 1981. Antibody-mediated enhancement of disease in 
feline infectious peritonitis: Comparisons with dengue hemorrhagic fever. 
Comparative Immunology, Microbiology and Infectious Diseases 4:175-189. 
72. Weiss RC, Scott FW. 1981. Pathogenesis of feline infectious peritonitis: 
nature and development of viremia. American Journal Veterinary Research 
42:382-390. 
73. Kipar A, Meli ML. 2014. Feline Infectious Peritonitis: Still an Enigma? 
Veterinary Pathology Online 51:505-526. 
74. Pedersen NC. 2009. A review of feline infectious peritonitis virus infection: 
1963–2008. Journal of Feline Medicine and Surgery 11:225-258. 
75. Holzworth J. 1963. Some Important Disorders of Cats. Cornell Veterinarian. 
76. Pedersen NC, Boyle JF, Floyd K, Fudge A, Barker J. 1981. An enteric 
coronavirus infection of cats and its relationship to feline infectious peritonitis. 
American Journal Veterinary Research 42:368-377. 
77. Poland A, Vennema H, Foley J, Pedersen NC. 1996. Two related strains of 
feline infectious peritonitis virus isolated from immunocompromised cats 
infected with a feline enteric coronavirus. Journal of Clinical Microbiology 
34:3180-3184. 
78. Dye C, Siddell SG. 2007. Genomic RNA sequence of feline coronavirus strain 
FCoV C1Je. Journal of Feline Medicine and Surgery 9:202-213. 
  39 
79. Brown M, Troyer JL, Pecon-Slattery J, Roelke ME, O'Brien SJ. 2009. 
Genetics and Pathogenesis of Feline Infectious Peritonitis Virus. Emerging 
Infectious Diseases 15:1445–1452. 
80. Vennema H, Poland A, Foley J, Pedersen NC. 1998. Feline Infectious 
Peritonitis Viruses Arise by Mutation from Endemic Feline Enteric 
Coronaviruses. Virology 243:150-157. 
81. Chang H, Egberink HF, Halpin R, Spiro DJ, Rottier PJM. 2010. Spike 
Protein Fusion Peptide and Feline Coronavirus Virulence. Emerging Infectious 
Diseases 18:1089-1095. 
82. Hartmann K, Binder C, Hirschberger J, Cole D, Reinacher M, Schroo S, 
Frost J, Egberink H, Lutz H, Hermanns W. 2003. Comparison of different 
tests to diagnose feline infectious peritonitis. Journal of Veterinary Internal 
Medicine 17:781-790. 
83. Pedersen N, Black J, Boyle J, Evermann J, McKeirnan A, Ott R. 1984. 
Pathogenic differences between various feline coronavirus isolates. 
Coronaviruses; molecular biology and pathogenesis. Advances Experimental 
Medicine Biology:365-380. 
84. Kummrow M, Meli ML, Haessig M, Goenczi E, Poland A, Pedersen NC, 
Hofmann-Lehmann R, Lutz H. 2005. Feline Coronavirus Serotypes 1 and 2: 
Seroprevalence and Association with Disease in Switzerland. Clinical and 
Diagnostic Laboratory Immunology 12:1209-1215. 
85. Herrewegh APM, Smeenk I, Horzinek MC, Rottier PJM, de Groot RJ. 
1997. Feline Coronavirus Type II Strains 79-1683 and 79-1146 Originate from 
a Double Recombination between Feline Coronavirus Type I and Canine 
Coronavirus. Journal of Virology 72:4508-4514. 
86. Hickman M, Morris J, Rogers Q, Pedersen N. 1995. Elimination of feline 
coronavirus infection from a large experimental specific pathogen-free cat 
breeding colony by serologic testing and isolation. Feline Practice 23:96-102. 
87. Black J. 1980. Recovery and in vitro cultivation of a coronavirus from 
laboratory-induced cases of feline infectious peritonitis. Veterinary Medicine 
Small Clinician 75:811-814. 
88. Pedersen N, Black J. 1983. Attempted immunization of cats against feline 
infectious peritonitis using either avirulent live virus or sublethal amounts of 
virulent virus. American Journal Veterinary Research 44:229-234. 
89. Porter E, Tasker S, Day MJ, Harley R, Kipar A, Siddell SG, Helps CR. 
2014. Amino acid changes in the spike protein of feline coronavirus correlate 
with systemic spread of virus from the intestine and not with feline infectious 
peritonitis. Veterinary Research 45. 
90. McKeirnan A, Evermann J, Hargis A, Ott R. 1981. Isolation of Feline 
Coronaviruses From Two Cats with Diverse Disease Manifestations. Feline 
Practice 11:16-20. 
91. Stoddart M, Scott F. 1989. Intrinsic resistance of feline infectious peritoneal 
macrophages to coronavirus infection correlates with in vivo virulence. Journal 
of Virology 63:436-440. 
  40 
92. Schwegmann-Wessels C, Zimmer G, Schroder B, Breves G, Herrler G. 
2003. Binding of transmissible gastroenteritis coronavirus to brush border 
membrane sialoglycoproteins. J Virol 77:11846-11848. 
93. Prat A, Seidah NG. 2012. The biology and therapeutic targeting of the 
proprotein convertases. Nature Reviews Drug Discovery 11:367+. 
94. Barrett A, Rawlings N, Woessner J. 2004. Handbook of Proteolytic 
Enzymes. Elsevier Academic Press. 
95. 2008. US Cats Product Overview: PRIMUCELL® FIP. Pfizer Animal Health. 
96. Wolf A. 1997. Feline infectious peritonitis, part 2. Feline Practice 25:24-28. 
97. Klepfer S, Reed AP, Martinez M, Bhogal B, Jones E, Miller TJ. 1995. 
Cloning and expression of FECV spike gene in vaccinia virus. Immunization 
with FECV S causes early death after FIPV challenge. Advances in 
experimental medicine and biology 380:235-241. 
98. Vennema H, de Groot RJ, Harbour DA, Dalderup M, Gruffydd-Jones T, 
Horzinek MC, Spaan WJ. 1990. Early death after feline infectious peritonitis 
virus challenge due to recombinant vaccinia virus immunization. Journal of 
Virology 64:1407-1409. 
99. Binn LN, Lazar EC, Keenan KP, Huxsoll DL, Marchwicki RH, Strano AJ. 
1974. Recovery and characterization of a coronavirus from military dogs with 
diarrhea. Proceedings, annual meeting of the United States Animal Health 
Association:359-366. 
100. Keenan KF, Jervis HR, Marchwicki RH, Binn LN. Intestinal infection of 
neonatal dogs with canine coronavirus 1-71: studies by virologic, histologic, 
histochemical, and immunofluorescent techniques. 
101. Erles K, Toomey C, Brooks HW, Brownlie J. 2003. Detection of a group 2 
coronavirus in dogs with canine infectious respiratory disease. Virology 
310:216-223. 
102. Erles K, Shiu KB, Brownlie J. 2007. Isolation and sequence analysis of 
canine respiratorycoronavirus. Virus Research 124:78-87. 
103. Decaro N, Buonavoglia C. 2008. An update on canine coronaviruses: Viral 
evolution and pathobiology. Veterinary Microbiology 132:221-234. 
104. Le Poder S. 2011. Feline and Canine Coronaviruses: Common Genetic and 
Pathobiological Features. Advances in Virology Advances in Virology 2011:1-
11. 
105. Pratelli A, Martella V, Pistello M, Elia G, Decaro N, Buonavoglia D, 
Camero M, Tempesta M, Buonavoglia C. 2003. Identification of 
coronaviruses in dogs that segregate separately from the canine coronavirus 
genotype. Journal of Virological Methods 107:213-222. 
106. Haijema BJ, Rottier PJ, de Groot RJ. 2007. Feline Coronaviruses: A Tale of 
Two-Faced Types, p. 183-203. In Thiel V (ed.), Coronaviruses. Moledular and 
Cellular Biology. Caister Academic Press, Norfolk, UK. 
107. Lorusso AN, Decaro P, Schellen P, Rottier PJ, Buonavoglia C, Haijema 
BJ, de Groot RJ. 2008. Gain, preservation, and loss of a group 1a coronavirus 
accessory glycoprotein. J. Virol 82:10312-10317. 
  41 
108. Pratelli A, Martella V, Elia G, Decaro N, Aliberti A, Buonavoglia D, 
Tempesta M, Buonavoglia C. 2001. Variation of the sequence in the gene 
encoding for transmembrane protein M of canine coronavirus (CCV). 
Molecular and Cellular Probes 15. 
109. Pratelli A, Martella V, Decaro N, Tinelli A, Camero M, Cirone F, Elia G, 
Cavalli A, Corrente M, Greco G. 2003. Genetic diversity of a canine 
coronavirus detected in pups with diarrhoea in Italy. Journal of Virological 
Methods 110:9-17. 
110. Decaro N, Martella V, Ricci D, Elia G, Desario C, Campolo M, Cavaliere 
N, Di Trani L, Tempesta M, Buonavoglia C. 2005. Genotype-specific 
fluorogenic RT-PCR assays for the detection and quantitation of canine 
coronavirus type I and type II RNA in faecal samples of dogs. Journal of 
Virological Methods 130:72-78. 
111. Buonavoglia CD, Nicola , Martella V, Elia G, Campolo MD, Costantina 
Castagnaro, Massimo Tempesta, Maria. 2006. Canine Coronavirus Highly 
Pathogenic for Dogs. Emerging Infectious Diseases 12:492-494. 
112. Ntafis V, Mari V, Decaro N, Papanastassopoulou M, Papaioannou N, 
Mpatziou R, Buonavoglia C, Xylouri E. 2011. Isolation, tissue distribution 
and molecular characterization of two recombinant canine coronavirus strains. 
Veterinary Microbiology 151:238-244. 
113. Wang Y, Ma G, Lu C, Wen H. 2006. Detection of canine coronaviruse 
sgenotype I and II in raised Canidae animals in China. Berliner und Münchener 
tierärztliche Wochenschrift 119. 
114. Soma T, Ohinata T, Ishii H, Takahashi T, Taharaguchi S, Hara M. 2011. 
Detectionandgenotyping of canine coronavirus RNA in diarrheic dogs in 
Japan. Research in Veterinary Science 90:205-207. 
115. Costa ME, Xavier de Castro T, de Oliveira Bottino F, Nasser Cubel 
Garcia RdC. 2014. Molecular characterization of canine coronavirus strains 
circulating in Brazil. Veterinary Microbiology 168:8-15. 
116. Escutenaire S, Isaksson M, Renström LHM, Klingeborn B, Buonavoglia 
C, Berg M, Belák S, Thorén P. 2007. Characterization of divergent and 
atypical canine coronaviruses from Sweden. Arch Virol 152:1507-1514. 
117. Krempl C, Schultze B, Laude H, Herrler G. 1997. Point mutations in the S 
protein connect the sialic acid binding activity with the enteropathogenicity of 
transmissible gastroenteritis coronavirus. Journal of Virology 71:3285-3287. 
118. Decaro N, Campolo M, Lorusso A, Desario C, Mari V, Colaianni ML, Elia 
G, Martella V, Buonavoglia C. 2008. Experimental infection of dogs with a 
novel strain of canine coronavirus causing systemic disease and lymphopenia. 
Veterinary Microbiology 128:253-260. 
119. Decaro N, Cordonnier N, Demeter Z, Egberink H, Elia G, Grellet A, Le 
Poder S, Mari V, Martella V, Ntafis V, von Reitzenstein M, Rottier PJ, 
Rusvai M, Shields S, Xylouri E, Xu Z, Buonavoglia C. 2013. European 
Surveillance for Pantropic Canine Coronavirus. Journal of Clinical 
Microbiology 51:83-88. 
  42 
120. Marinaro M, Mari V, Bellacicco AL, Tarsitano E, Elia G, Losurdo M, 
Rezza G, Buonavoglia C, Decaro N. 2010. Prolonged depletion of circulating 
CD4+ T lymphocytes and acute monocytosis after pantropic canine 
coronavirus infection in dogs. Virus Research 152:73-78. 
121. Decaro N, Martella V, Elia G, Campolo M, Desario C, Cirone F, Tempesta 
M, Buonavoglia C. 2007. Molecular characterisation of the virulent canine 
coronavirus CB/05 strain. Virus Research 125:54-60. 
122. Zappulli V, Caliari D, Cavicchioli L, Tinelli A, Castagnaro M. 2008. 
Systemic fatal type II coronavirus infection in a dog: Pathological findings and 
immunohistochemistry. Research in Veterinary Science 84:278-282. 
123. Decaro N, Mari V, Campolo M, Lorusso A, Camero M, Elia G, Martella 
V, Cordioli P, Enjuanes L, Buonavoglia C. 2009. Recombinant Canine 
Coronaviruses Related to Transmissible Gastroenteritis Virus of Swine Are 
Circulating in Dogs. Journal of Virology 83:1532-1537. 
124. Wesley RD. 1999. The S gene of canine coronavirus, strain UCD-1, is more 
closely related to the S gene of transmissible gastroenteritis virus than to that 
of feline infectious peritonitis virus. Virus Research 61:145-152. 
125. Carmichael LE. 1999. Canine viral vaccines at a turning point—A personal 
perspective. Advances in Veterinary Medicine 41:289-307. 
126. Gallagher TM, Buchmeier MJ. 2001. Coronavirus spike proteins in viral 
entry and pathogenesis. Virology 279:371-374. 
127. Wentworth D, Holmes KV. 2001. Molecular determinants of species 
specificity in the coronavirus receptor aminopeptidase N (CD13): Influence of 
N-linked glycosylation. . Journal of Virology 75. 
128. Hohdatsu T, Yamada M, Tominaga R, Makino K, Kida K, Koyama H. 
1998. Antibody-Dependent Enhancement of Feline Infectious Peritonitis Virus 
Infection in Feline Alveolar Macrophages and Human Monocyte Cell Line 
U937 by Serum of Cats Experimentally or Naturally Infected with Feline 
Coronavirus. Journal of Veterinary Medical Science 60:49-55. 
129. Van Hamme E, Desmarets L, Dewerchin HL, Nauwynck HJ. 2011. 
Intriguing interplay between feline infectious peritonitis virus and its receptors 
during entry in primary feline monocytes. Virus Research 160:32-39. 
130. Licitra BN, J.K. M, Regan AD, Hamilton BS, Rinaldi VD, Duhamel GE, 
Whittaker GR. 2013. Mutation in spike protein cleavage site and 
pathogenesis of feline coronavirus. Emerging Infectious Diseases 19:1066-
1073. 
131. Greene CE, Decaro N. 2011. Canine Viral Enteritis. In Greene CE (ed.), 
Infectious Diseases of the Dog and Cat 4th ed. Elsevier Health Sciences. 
132. Pollock RV, Carmichael LE. 1983. Canine viral enteritis Veterinary Clinics 
of North Amercia: Small Animal Practice 13:551-566. 
133. Saif LJ, Theil KW. 1989. Viral Diarrheas of Man and Animals. CRC Press, 
Boca Raton, FL, USA. 
134. Pratelli A, Tempesta M, Roperto FP, Sagazio P, Carmichael L, 
Buonavoglia C. 1999. Fatal Coronavirus Infection in Puppies following 
  43 
Canine Parvovirus 2b Infection. Journal of Veterinary Diagnostic Investigation 
11:550-553. 
135. Appel MJG. 1988. Does canine coronavirus augment the effects of subsequent 
parvovirus infection? Veterinary Medicine 83:360-366. 
136. Evermann JF, Abbott JR, Han S. 2005. Canine Coronavirus-Associated 
Puppy Mortality without Evidence of Concurrent Canine Parvovirus Infection. 
Journal of Veterinary Diagnostic Investigation 17:610-614. 
137. Naylor MJ, Monckton RP, Lehrbach PR, Deane EM. 2001. Canine 
coronavirus in Australian dogs. Australian Veterinary Journal 79:116-119. 
138. Naylor MJ, Walia CS, McOrist S, Lehrbach PR, Deane EM, Harrison GA. 
2002. Molecular Characterization Confirms the Presence of a Divergent Strain 
of Canine Coronavirus (UWSMN-1) in Australia. Journal of Clinical 
Microbiology 40:3518-3522. 
139. Naylor MJ, Harrison GA, Monckton RP, Mcorist S, Lehrbach PR, Deane 
EM. 2001. Identification of canine coronavirus strains from feces by S gene 
nested PCR and molecular characterization of a new Australian isolate. Journal 
of Clinical Microbiology 39:1036-1041. 
140. Graham RL, Baric RS. 2010. Recombination, reservoirs, and the modular 
spike: Mechanisms of coronavirus cross-species transmission. Journal of 
Virology 84. 
141. LePoder S, D’orangiani AL, Duarte L, Fournier A, Horhogea C, Pinhas C, 
Vabret A, Eloit M. 2013. Infection of cats with atypical feline coronaviruses 
harbouring a truncated form of the canine type I non-structural ORF3 gene. 
Infection, Genetics and Evolution 20. 
142. Decaro N, Pratelli A, Campolo M, Elia G, Martella V, Tempesta M, 
Buonavoglia C. 2004. Quantitation of canine coronavirus RNA in the faeces 
of dogs by TaqMan RT-PCR. Journal of Virological Methods 119:145-150. 
143. Gizzi AB, Oliveira ST, Leutenegger CM, Estrada M, Kozemjakin DA, 
Stedile R, Marcondes M, Biondo AW. 2014. Presence of infectious agents 
and co-infections in diarrheic dogs determined with a real-time polymerase 
chain reaction-based panel. . BMC Veterinary Research 10:23. 
144. Greene CE, Levy JK. 2012. Immunoprophylaxis. In Infectious Diseases of 
the Dog and Cat. In Greene CE (ed.). Elsevier Saunders, St. Louis, MO, USA. 
 
 
 
 
 
 
  44 
CHAPTER TWO 
 
Mutation in Spike Protein Cleavage Site and Pathogenesis of Feline Coronavirus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Licitra BN, J.K. M, Regan AD, Hamilton BS, Rinaldi VD, Duhamel GE, 
Whittaker GR. 2013. Mutation in spike protein cleavage site and pathogenesis of 
feline coronavirus. Emerging Infectious Diseases 19:1066-1073. 
  45 
2.1 Introduction 
Feline infectious peritonitis (FIP) is a fatal infection that affects domestic and wild 
members of the family Felidae and is caused by a feline coronavirus (FCoV) of the 
family Coronaviridae, subfamily Coronavirinae, genus Alphacoronavirus, species 
Alphacoronavirus-1 (1). The FCoV genome is approximately 29 kB and has 11 open 
reading frames encoding replicative, structural, and accessory proteins (2). Two 
serotypes have been identified. Serotype 1 FCoVs are highly prevalent clinically (3–5) 
but grow poorly in cell culture and are therefore under evaluated when compared with 
serotype 2 FCoVs, which are easily propagated in-vitro but less prevalent. 
Within each serotype, there are 2 biotypes, each causing distinct disease outcomes. 
Feline enteric coronavirus (FECV) of serotypes 1 and 2 infects enterocytes, causing 
mild and generally self-limiting infections. FECV spreads efficiently through the oral–
fecal route, and chronically infected cats can shed infectious virus in feces for a year 
or longer (6,7). The second biotype found in both serotypes, FIP virus (FIPV) is found 
less frequently but causes FIP. 
The current understanding is that FIPV arises during in vivo infection from a genetic 
mutation of FECV (8–11). A long-standing hypothesis is that FIP viruses arise from 
internal mutation of endemic FECVs (12), which is believed to occur in approximately 
1%–5% of enteric infections, resulting in the ability of the virus to infect blood 
monocytes and tissue macrophages. The resulting productive infection of these cells, a 
hallmark of FIP, enables systemic spread and results in macrophage activation, with 
concomitant immune-mediated events leading to death. To date, the precise mutation 
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or mutations that cause a shift in FCoV biotype have not been identified. 
As with other RNA viruses, coronavirus replication is error-prone; the estimated 
mutation rate is approximately 4 × 10 nucleotide substitutions/site/year (13,14). It has 
been suggested that mutations in the 3c and 7b genes may be involved in the transition 
to FIPV (1,12,15). Because FCoV spike protein plays critical roles in receptor binding 
(S1) and fusion (S2), we focused on structural changes in this protein and potential 
role in altered cellular tropism. In particular, acquisition of macrophage tropism for a 
serotype 2 FCoV has previously been mapped to the spike gene (16), further 
suggesting that key mutations within spike protein may be important for the biotype 
switch. 
The coronavirus spike protein is a class I fusion protein, which typically requires 
activation by cellular proteases. Mutation of the proteolytic cleavage site often has 
profound implications for disease progression (17,18). Until recently, FCoVs were 
thought to have uncleaved spike proteins. However, a functional furin cleavage site 
has been identified in 2 serotype 1 FECVs, located at the shared boundary of the S1 
and S2 subunits (19). Furin is a ubiquitous proprotein convertase enriched in the trans-
Golgi network and is well-conserved among mammals (20). Furin cleaves a wide 
range of protein precursors into biologically active products at a consensus motif R-X-
K/R-R, where R is the basic arginine residue, X is any residue, and K is the basic 
lysine residue (21). 
In this article, we establish a novel approach to studying FIP that complements 
previous work. Instead of performing a mutation study based mainly on comparative 
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genetic analysis (15,22–24), we focus on S1/S2, a functionally relevant site, and study 
variations between the biotypes and their functional effects. This rationale could 
provide a better means to uncover functionally important mutations that account for 
FIP. 
We considered that mutations at the S1/S2 site could alter proteolytic cleavage and 
modify S fusogenic properties, leading to tropism expansion, systemic spread and, 
ultimately, FIP. We investigated genetic variations at the S1/ S2 site of serotype 1 
FECVs and compared these sequences to those present in viral RNA recovered from 
tissues of cats with FIP. Fluorogenic peptide cleavage assays were conducted to assess 
the effects of substitutions found in the S1/S2 site. We document a junction mutation 
at S1/S2 that arises during development of FIP. Our study has uncovered a molecular 
basis for FIP that has potential to lead to developments in diagnostics, prevention, and 
therapies. 
2.2 Materials and Methods 
FCoV Sequence Analysis 
Clinical and demographic data are reported in Technical Appendix Table 1.  Fecal 
samples from asymptomatic infected domestic cats were solicited from shelters and 
veterinarians throughout the United States. RNA was extracted by using QIAamp 
Viral RNA Mini Kit (QIAGEN, Valencia, CA, USA). FCoV primers that detect most 
circulating strains were used to screen all fecal samples (25). RNA extracted from 
FIPV-TN406 (Black) laboratory-adapted strain was used as a positive control. 
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We analyzed 22 FIPV-positive tissue samples (Veterinary Pathology Archives, 
Cornell University, Ithacan, NY, USA) from 11 cats with FIP. Diagnosis of FIP was 
based on the standard method of immunohistochemical evaluation by board-certified 
pathologists. Each sample was retrieved from formalin-fixed, paraffin-embedded 
tissue blocks from which sections were stained by using FIPV 3–70 antibody (Custom 
Monoclonals, Sacramento, CA, USA). Positively stained regions were thinly sectioned 
and RNA was extracted by using RecoverAll (Ambion, Foster City, CA, USA). 
Fecal samples collected from FCoV-positive housemates, cats 234 and 304, were 
processed as previously described in this section. After the referring veterinarian made 
a diagnosis of FIP in cat 234, the owner elected to euthanize the animal. Fresh tissue 
was harvested and RNA extracted by using MagMAX Express (Life Technologies, 
Grand Island, NY, USA). 
For all samples, 50 μL reverse transcription PCRs (RTPCRs) were performed with 
One-Step RT-PCR (QIAGEN) by using gene-specific S primers, encompassing S1/S2. 
The PCR primers sequences are found in Technical Appendix Table 2. PCR 
conditions were 30 min at 50°C, 15 min at 95°C, and 39 or 35 cycles of 1 min at 94°C, 
1minat 55°C, 1 or 1.5 min at 72°C, and 10 min at 72°C. PCR products were purified 
by using a QIAquick Gel Extraction Kit (QIAGEN). Sanger sequencing was 
performed at the Life Sciences Core Laboratories (Cornell University). Nucleotide 
archive accession numbers are shown in Technical Appendix Table 4. DNA sequences 
were translated into protein sequences and alignments were performed by using 
Geneious 5.4 (Biomatters Ltd., Auckland, New Zealand). Sequence logos were 
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generated by using Weblogo 3.1 (http://weblogo.threeplusone.com/). Statistical 
analysis was performed by using 2-tailed Fischer exact test. In the test, the numbers of 
FIPV-infected and FECV-infected cats were counted. For each category of FIPV or 
FECV infection, cats harboring viruses with or without mutations at the S1/S2 site 
were counted. 
Furin Cleavage Assay 
Fluorogenic 12-mer peptides were designed and synthesized by RS Synthesis, 
Louisville, KS, USA (Technical Appendix Table 3). Purified recombinant human 
furin was purchased from NEB (Ipswich, MA, USA). For each reaction, 1 unit of 
enzyme was used in 100 μL final volume by using the reaction buffer 100 nmol/L 
HEPES, 0.5% Triton X-100, 1 mmol/L CaCl2, 1 mmol/L 2-mercaptoethanol, pH 7.5. 
Peptides were diluted to 50 μmmol/L. Reactions were performed in triplicate at 30°C 
and fluorescence was measured with a SpectraMax fluorometer (Molecular Devices, 
Sunnyvale, CA, USA), enabling Vmax determination. Results for each peptide are 
expressed as percent cleavage by furin compared with the canonical sequence. 
To perform comparative analysis of the S1/S2 cleavage site between FECVs and 
FIPVs, we identified cases of FIP that were confirmed postmortem by using 
immunohistochemistry, the standard for FIP diagnosis; archival 
immunohistochemistry-positive formalin-fixed tissues were used as the source of 
FIPV RNA. To ensure good quality sequence information from archival material, the 
RT-PCR amplicon size was limited to 160bp (including the S1/S2 site). This same 
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region was then amplified from fecal material from coronavirus-positive healthy cats. 
2.3 Results 
FECV S1/S2 
Sequencing of the S1/S2 site of 30 S sequences from FECV fecal samples revealed an 
extremely well-conserved motif at the amino acid level (Figure 1, panel A). In 
particular, arginine (R) residues are found exclusively at the most critical positions for 
furin recognition and cleavage (P1, P2, and P4) in all sequences analyzed (Figure 2, 
panel B). The P1′ position is extremely well conserved, because serine (S) is found in 
100% of cases. The P5 position is also well conserved, evidenced by a clear majority 
of basic residues found (96.6% arginine or lysine [K]; Figure 2, panel B). At P3, 
limited variability is found (76.7% serine and 23.3% alanine [A]). Overall, 100% of 
FECV sequences analyzed contain the furin cleavage site, with a core motif of R-R-
S/A-R-R-S. 
FIPV S1/S2 
Analysis of the S1/S2 cleavage site of FIPV sequences shows that it has much more 
variability, both within the narrow furin cleavage recognition motif (P4-P1) and in 
residues extending out of it (P8-P5 and P2′-P4′) (Figure 2A). A striking observation is 
that the critical positions P1 and P2 are among the most consistently mutated (Figure 
3). To a lesser degree, variability extends to other positions of the cleavage motif, 
notably in the P1′, P3, P4, and P5 positions (Figure 2). Examination results of the 
entire portion of spike sequenced in this study indicate that the conserved R-R-S/A-R-
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R-S motif in FECV is present within a region of the spike gene that shows a high 
degree of variability, in contrast to other neighboring regions that are more highly 
conserved (Technical Appendix Figure 1). 
Correlation between FIP Status of Cats and Presence of Mutations at S1/S2 
A Fisher exact test was performed to establish whether a correlation existed between 
the FIP status of the sampled cats and mutations at the S1/S2 site of viruses analyzed 
(Table 1). The test unequivocally demonstrated that there was a strong correlation 
(p<0.0001) between FIP and presence of mutations at S1/S2. 
Table 2.1 Fisher Exact Test Tabulation.  Status of cats sampled for feline coronavirus 
and mutations in spike protein cleavage site 
  
  
  
FECV-  FIPV-  Total 
               infected cats    infected cats 
 
 
Cats harboring viruses with  2  10  12 
≥ 1 mutated S1/S2 residue 
 
Cats harboring viruses with 28  1  29 
an intact S1/S2 site 
 
Total    30  11  41   
 
FECV, feline enteric coronavirus; FIPV, feline infectious peritonitis virus; S1, 
receptor binding domain of spike; S2, fusion domain of spike 
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Fluorogenic Peptide Furin Cleavage Assay 
To test whether the identified FIPV S1/S2 mutations have an effect on cleavability by 
furin, we performed an in vitro proteolytic assay. We used human furin for these 
experiments. Human and feline furin are very similar (96% identical) and are expected 
to cleave in an equivalent manner. However, feline furin has not been directly studied 
to any degree, and reagents are not readily available. Feline and human cells lines 
show identical rates of cleavage for a known furin target protein (PSCK-9), which 
contains an active furin cleavage site (Technical Appendix Figure 2). We used 
fluorogenic peptides containing the canonical motif (RR-S-R-R-S) or with 
substitutions from positions P1′ through P7 (Figure 4, panel A). The canonical peptide 
was efficiently cleaved by furin (Figure 4), with average Vmax of 235 Relative 
Fluorescence Units (RFU) per minute. 
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Figure 2.1 Sequence analysis of feline enteric coronavirus (FECV) spike S1/S2 site. RNA 
from 30 FECVs collected from 30 fecal samples obtained from subclinically infected cats was 
extracted, purified, and reverse-transcribed into cDNA. Sequencing of the spike gene was 
performed in a region surrounding the S1/S2 cleavage site. A) Sequence alignment. Sequence 
identification row (blue font): residue positions in the S1/S2 cleavage site from P8 to P4′. Red 
arrow indicates the site of furin cleavage. B) To visualize the diversity of residues at each 
position of the S1/S2 site, sequences were subjected to WebLogo 3.1 analysis 
(http://weblogo.threeplusone. com/create.cgi). Top: WebLogo for the 30 FECV S1/S2 
sequences with the frequency of residue found at each position displayed. Bottom: summary 
of the diversity of residues for each position from P4 to P1′ and percentages of each amino 
acid represented. 
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Figure 2.2 Sequence analysis of feline infectious peritonitis virus (FIPV) spike S1/S2 
site. RNA from 22 FIPVs collected from 11 cats that had feline infectious peritonitis 
was extracted, purified, and reverse-transcribed into cDNA. Sequencing of the spike 
gene was performed in a region surrounding the S1/S2 cleavage site. A) Sequence 
alignment. Sequence identification row (blue font): residue positions in the S1/S2 
cleavage site from P8 to P4′. Red arrow indicates the site of furin cleavage. B) To 
visualize the diversity of residues at each position of the S1/S2 site, sequences were 
subjected to WebLogo 3.1 analysis (http://weblogo.threeplusone.com/create.cgi). Top: 
WebLogo for the 22 FIPV S1/S2 sequences with the frequency of residue found at 
each position displayed. Bottom: summary of the diversity of residues for each 
position from P4 to P1′ and percentages of each amino acid represented. 
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Figure 2.3 Amino acid substitution frequency at each position of the feline infectious 
peritonitis virus S1/S2 cleavage site. The histogram is based on feline infectious 
peritonitis virus S1/S2 WebLogo 3.1 analysis  
(http://weblogo.threeplusone.com/create.cgi), showing percentage of modification of 
residues at each position of the S1/ S2 site, compared with feline enteric coronavirus 
S1/S2 canonical sequence consensus. 
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Within the P4-P1′ core peptide, in the canonical background, when the P1′ serine 
residue is changed into a leucine (L), furin cleavage is severely diminished (8% of 
canonical cleavage rate), a result that shows the key role of the conserved P1′ serine. 
Modifications of the P1 arginine in the canonical peptide, regardless of the residue 
tested, for example, glycine (G), methionine (M) or threonine (T), abrogate cleavage 
by furin (Figure 4). Modifications at the P2 arginine residue in the canonical peptide 
have variable effects. When P2 arginine is changed to histidine (H), there is complete 
inhibition (0% of canonical cleavage). When P2 is changed to leucine or serine, 
cleavage efficiency is reduced by approximately 50% and 20%, respectively. When P2 
is modified to proline (P), cleavage efficiency slightly increases to 129% of the 
canonical peptide (Figure 4). The P3 S-A substitution minimally enhances cleavage 
(Figure 4). P4 arginine is another residue position that is essential for furin cleavage. 
In the canonical peptide, P4 R-K substitution, there is a slight decrease in cleavage 
efficiency (88.7% of canonical rate). In contrast, when the P4 arginine is substituted 
with glycine, furin cleavage is completely abrogated (Figure 4). 
For positions upstream of P4, while P5 R-K and P6 T-F modifications have moderate 
enhancing effects on furin cleavage (149% and 162% of canonical rate, respectively), 
the P7 H-Q peptide shows a substantial increase in its cleavability (186% compared 
with canonical). The P7 H-Q P5 R-K peptide shows that the effect of each 
modification can be additive (232% compared with canonical peptide) (Figure 4). 
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Figure 2.4 Furin cleavage assays of fluorogenic peptides. A) Synthetic fluorogenic 
peptides were generated with sequences matching consensus feline enteric coronavirus 
and a panel of modified sequences with substitutions (underlined) found by feline 
infectious peritonitis virus sequencing. Peptides (50 μmol/L) were subjected to 
cleavage by recombinant human furin (1 U/100 μL), at pH 7.5, 30°C, and the release 
of fluorescence over time was measured by a spectrofluorometer enabling calculation 
of the Vmax of each reaction. Peptide cleavage scores generated by the ProP 1.0 
server (www.cbs.dtu.dk/services/ProP/) are also displayed. B) For each modified 
peptide (substitutions underlined), the percentage of cleavage rate compared with the 
canonical sequence was calculated and displayed. Cleavage assays were performed in 
>3 independent experiments. Error bars indicate SD for each measurement. 
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Functionally Relevant S1/S2 Mutation 
To further confirm our findings, we analyzed the S1/ S2 sites from viral samples taken 
from cats 234 and 304, who lived in the same household (Table 2). At the initial 
sampling in 2009 (t = 1), both cats were asymptomatic for FIP and were shedding 
FCoV in their feces. In samples from both cats, the S1/S2 sites had a core sequence R-
R-S-R-R-S consistent with the FECV consensus. Upon the second sampling in 
2011/2012 (t = 2), FIP was diagnosed in cat 234. Cat 304 remained asymptomatic but 
continued to shed virus in feces. Notably, when the S1/ S2 sequences were analyzed at 
the second sampling, only the cat with FIP (234) had a change in the FECV consensus 
sequence (a P2 R-L mutation). While exhibiting a change in the P3 residue (S-A), the 
virus present in cat 304 retained the conserved S1/S2 furin cleavage motif (Table 2). 
These data provide direct evidence of mutations in spike linked with development of 
FIP in cats. 
Table 2.2 Sequence of FCoV spike at S1/S2 junction in cats sampled for feline 
coronavirus* 
  
  
Time            Cat # 234                Cat # 304      
 
 
t = 1  NHTHTRRSRR∨SAPVAV  NHTHTRRSRR∨SAPVAV 
 
t = 2   NHTHTRRSLR∨SAPVAV  NHTHTRRARR∨SAPVAV 
 
* Underlines indicate nucleotide substitution.  FCoV, feline coronavirus; S1/S2, 
cleavage site of spike protein; t =1 both cats disease-free; ∨, position of cleavage; t = 2 
cat #234 feline infectious peritonitis positive, cat #304 disease free 
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2.4 Discussion 
To study FIP, we have taken an alternative approach that complements earlier studies 
that were based on analytical outcomes of putative FIP-causing mutations and 
inference of their functional consequences. We focused on the S1/S2 sequence, a 
specific and functionally highly relevant cleavage site within the S protein, and 
documented mutations between asymptomatic and highly symptomatic cats that 
correlated strongly with FIP. We also documented a functional S1/S2 cleavage site 
mutation that arose in an asymptomatic cat that subsequently developed FIP. 
Our sequence data show that serotype 1 FECV from feces of asymptomatic cats 
contain a highly conserved furin cleavage motif at the S1/S2 site, with the following 
narrow range of residues: (R>>K/G)P5-(R)P4-(S>A)P3-(R)P2(R)P1-(S)P1′. In addition to 
the consensus R-X-K/R-R motif, additional flanking residues can also be 
consequential for furin-mediated cleavage (26–28). In particular, a serine (S) residue is 
critical in the P1′ position (29) and it is notable that all FECVs examined contained a 
P1′ S residue. The fact that the S1/S2 site is extremely well conserved is an indication 
that it is functionally essential for FECV replication in the enteric epithelium. 
In contrast to the situation for asymptomatic cats infected with FECV, we found that 
sequences of FCoV sampled from tissue of confirmed FIP-positive cats consistently 
have mutations at the S1/S2 site. In the most critical position for furin cleavage, P1, 
we found that >40% of FIPVs have a mutation in the arginine residue, which is 
replaced by an aliphatic (methionine and glycine) or polar uncharged (threonine) 
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residue. Overall, the distinguishing feature of FIPVs is the absence of the P1 arginine, 
rather that the presence of any particular residue. This is corroborated by our peptide 
cleavage data that demonstrate that furin cleavage is fully abrogated for all P1 
substitutions tested. The next most common position mutated in FIPV is P2; >30% of 
the FIPVs analyzed bore mutations at this position. Most mutated residues found were 
aliphatic (P and L). Some sequences were substituted with a polar basic (H) or a polar 
uncharged (S) residue. Apart from the P2 R-P substitution, peptide cleavage data 
indicates that all other substitutions have an inhibiting effect on furin cleavage. Of 
note, for murine hepatitis virus (MHV), a betacoronavirus that also harbors an S1/S2 
cleavage site in its spike protein, there is a precedent for the inhibitory effect of the 
introduction of a histidine in the P2 position of the cleavage site. Two well-studied 
strains, MHV strain A59 (MHV-A59) and the neurovirulent MHV strain JHM (MHV-
JHM), have a notable difference at this site. MHV-A59 has an RR-S-H-R-S sequence 
and is less efficiently cleaved than MHV-JHM, which has an R-R-A-S-S-R sequence 
(18). P4 is generally considered to be critical for furin cleavage, but we found limited 
variation in this residue position for the FIPVs tested and found mutation to the polar 
basic residue (K) or polar uncharged residue (S) in <5% of viruses. The peptide data 
indicates that, although introduction of a serine at P4 completely abrogates cleavage, 
the P4 R→K substitution has minimal effect. The FIPV P3 position showed small 
variation compared with FECV after the introduction of a polar uncharged residue (T) 
in 1 sample. For the P5 position, the only change was a slightly higher frequency of 
the lysine residue in samples from cats with FIPV. Peptide cleavage data indicated that 
the common S-A substitution found for FECV and FIPV P3 positions has only slightly 
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increasing effect on proteolysis by furin. Furthermore, the P5 R→K substitution has 
an enhancing effect in the peptide cleavage assay. At P1′, the conserved polar 
uncharged residue (S) was retained in the majority of FIPV samples, however, the 
introduction of an aliphatic amino acid (L) was found. It is notable that furin cleavage 
has been suggested to be incompatible with a hydrophobic aliphatic side chain, with a 
strong preference for serine in the P1′ position (27,29). In the D04-397-2 sample 
containing the P1′ L, the basic residues within the S1/S2 site remain identical to the 
ones found in FECV sequence; we suggest that disruption of furin cleavage is 
mediated by a mutation in P1′, rather than the more typical P1, P2 and/or P4 mutation. 
This hypothesis is supported by the peptide cleavage assay, where the P1′S-L peptide 
is unable to be cleaved by furin. 
Overall, in terms of FIP-positive animals, we found that 10 of 11 cats harbored viruses 
with mutations in the furin motif R-R-S/A-R-R-S found in FECV of asymptomatic 
cats. For most FIP-positive cats, we sequenced viral RNA collected from different 
tissues (Technical Appendix Table 1). Our data provides strong support for the 
internal mutation hypothesis, as the mutations are unique to individual cats. 
Of note, not all tissues from the same animal carry the same mutation. In some 
instances, mixed populations of viruses exist within the same animal. The majority of 
viruses sequenced had 1 mutation, although 5 (D06-244-1, D06244-2, 08-153990-2, 
N07-95-1, and D04-93-2) had 2 mutations. However, there are 2 apparent exceptions 
of cats harboring viruses that do not have clearly defined mutations in the furin 
cleavage site: samples from cat 151643 (1–3) and samples from cat N05-110 (1,2). 
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We consider that the presence of a P6 furin cleavage in samples of cat 151643 is 
consistent with our hypothesis of a switch in the activating protease for the virus, 
because this is not typical of naturally occurring furin cleavage sites. Samples 1 and 2 
from cat N05-110 harbor virus with an atypical lysine residue at P5. While unusual for 
FECVs, a P5 lysine residue does appear to be compatible with furin cleavage, so it 
remains to be determined how noteworthy a P5 lysine residue versus a P5 arginine 
residue is in the context of a protease switch for FIPV, or whether other mutations 
correlated with FIPV in the case of this cat. 
As part of our study, we analyzed field samples from cats harboring FCoV at different 
times. In cat 234, the virus underwent a transition from FECV to FIPV, and had a 
functionally relevant mutation in the S1/S2 motif (P2 R-L). Cat 304, living in the same 
house as cat 234, remained asymptomatic. Cat 304 harbored a mutated virus, but the 
mutation was in a functionally irrelevant position (P3 S-A). Identification of cats with 
FECV in which FIP subsequently develops is challenging, and while we present a 
single example, we consider these data to be strong evidence that mutations at the 
S1/S2 site are linked to a change in the pathogenic properties of the virus, and likely to 
be essential for the acquisition of macrophage tropism seen in FIP . 
The S1/S2 cleavage site and surrounding residues of serotype 1 FIPV S sequences 
were found to be systematically modified by mutations. Chang et al. recently 
published an extensive comparative analysis of FIP mutations at the nucleotide level 
by performing whole-genome sequencing of FECVs and FIPVs; the authors found a 
site within S (nucleotide position 23531), but outside of S1/ S2, to be the most 
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frequently mutated in FIPV (15). We have undertaken an analysis of the S1/S2 sites 
sequenced by Chang et al. and find that our hypothesis that mutation within the S1/S2 
furin motif correlates with FIP in ≈64% of their samples. There are 3 differences in 
methodology that may explain this lack of agreement: first, we employed 
immunohistochemistry to confirm the diagnosis of FIP, while Chang et al. reported 
using postmortem examination; second, all FIP samples in this study originate from 
tissue, while Chang et al. included both tissue and ascites fluid; and finally, we report 
multiple sequences for FIP-affected cats, while Chang et al. reported a single 
sequence. Sequence data from samples D04-397-1 and D04-397-2 provide evidence 
that both FECV and FIPV populations can be identified within an affected animal. 
Sequence information from a single sample may not be adequate for the detection of 
mutated virus. 
Most mutations negatively affect furin processing, but some enhance it. Given that the 
majority of the FIPV S proteins still harbor basic residues at the S1/S2 boundary, it 
could be reasoned that the mutated site becomes more open and can be cleaved by a 
range of other proteases. The switch in proteolytic requirements of S that we propose 
may offer an explanation for the crucial tropism transition during FIP. A possible 
consequence of the mutations is cleavability by monocytic/macrophage-specific 
proteases. These could be pro-protein convertases, cathepsins, or other 
macrophagespecific proteases. In particular, cathepsin B, matrix metalloproteases, and 
furin-related PCSK1 are likely to be expressed on the surface of macrophages and 
recognize the hallmark residues remaining or acquired in FIPV S1/S2 cleavage site 
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(30). Matrix metalloprotease 9 is of particular interest because it was demonstrated to 
be upregulated in activated monocytes and macrophages during FIP (31). A shift in 
the entry pathway to enable virus entry at the cell surface instead of the endosome may 
simultaneously explain the ability of FIPV to infect macrophages and the macrophage 
resistance of FECV. It is also possible that the mutations in the S1/S2 region affect the 
heparin sulfate binding site in this region (19). However, heparin sulfate binding is a 
cell culture adaptation of the virus, and as so, its relevance to the clinical situation 
would appear to be unlikely. 
A contrasting view to the internal mutation hypothesis to explain the genesis of FIP 
outbreaks is that there is a circulating FCOV other than FECV that is specific for FIP 
(22). For a complex disease process such as FIP, we and others consider it likely that 
there may be circulating FECVs that are closer to making the critical mutations 
necessary for FIP, possibly explaining paradoxical FIP outbreaks (32). Based on the 
data we present here, we conclude that mutation of the S1/S2 locus and modulation of 
a furin recognition site normally present in the S gene of FECVs is a critical 
contributing factor for development of FIP. Further studies could serve to analyze how 
S1/S2 mutations fit with the other mutations posited to account for FIP development. 
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Technical Appendix Table 1.  Clinical and demographic data from 44 domestic cats sampled in the continental United States from 
2004–2012 
Cat no. Sample no. FECV/FIPV Sample Type Year State Sequence 
20 - FECV Feces 2008 PA THTRRSRRSAPA 
10 - FECV Feces 2008 PA THTRRSRRSAPI 
36 - FECV Feces 2008 PA THTRRSRRSAPV 
106 - FECV Feces 2010 CT TQSRRSRRSYPD 
110 - FECV Feces 2010 CT TQTRRSRRSTSE 
111 - FECV Feces 2010 CT THSRRARRSTVE 
125 - FECV Feces 2010 WI TQSRRARRSQFE 
126 - FECV Feces 2010 WI TQSRRSRRSASS 
128 - FECV Feces 2010 WI THSRRARRSTVE 
129 - FECV Feces 2010 WI TQSRRSRRSTSD 
131 - FECV Feces 2010 WI TQSRRSRRSASN 
132 - FECV Feces 2010 WI TQSRRSRRSAPE 
135 - FECV Feces 2010 IA TQSRRARRSLPA 
136 - FECV Feces 2010 IA TQSRRSRRSVVE 
137 - FECV Feces 2010 IA TSSRRSRRSTPE 
138 - FECV Feces 2010 IA TQSRRSRRSVAE 
140 - FECV Feces 2010 IA TQSRRSRRSVVE 
141 - FECV Feces 2010 IA TQSRRSRRSVVE 
142 - FECV Feces 2010 IA THSRRARRSTVE 
143 - FECV Feces 2010 IA TSSRRARRSSVE 
144 - FECV Feces 2010 IA TQSRRSRRSASM 
146 - FECV Feces 2010 CA THSRRARRSTVE 
149 - FECV Feces 2010 NY TSSRRSRRSTPE 
150 - FECV Feces 2010 NY TSSRRSRRSTTE 
152 - FECV Feces 2010 MI THSRRSRRSNSD 
153 - FECV Feces 2010 NY PHSRRSRRSTNY 
155 - FECV Feces 2010 NY THSGRSRRSASD 
167 - FECV Feces 2010 RI THSKRSRRSTSN 
4594 - FECV Feces 2004 MD TQQRRSRRSTSD 
4582 - FECV Feces 2004 MD TQQRRSRRSTSD 
D06 327 1 FIPV Spleen 2006 NY THSRRSRGSAPN 
D06 327 2 FIPV Mesentery 2006 NY THSRRSRGSAPN 
D06 244 1 FIPV Mesenteric lymph node 2006 MI TQSRRASTSTSN 
D06 244 2 FIPV Mesentery 2006 MI TQSRRASTSTSN 
D05 77 1 FIPV Kidney 2005 NC THSRRSRMSTQN 
D05 77 2 FIPV Cerebellum 2005 NC THSRRSLRSTQN 
07 129308 1 FIPV Mesentery 2007 NY TSSRRSPRSTLD 
08 153990 1 FIPV Kidney 2008 PA TQPRRARMSVPE 
08 153990 2 FIPV Brain stem 2008 PA TQPRRAPMSVPE 
08 153990 3 FIPV Cerebrum 2008 PA TQPRRARMSVPE 
08 153990 4 FIPV Cerebellum 2008 PA TQPRRARMSVPE 
N05 48 1 FIPV Cerebellum 2005 VA TQSRSSRRSTSD 
N05 110 1 FIPV Mesenteric lymph node 2005 NY TQTKRSRRSTPQ 
N05 110 2 FIPV Cerebellum 2005 NY TQTKRSRRSTPA 
N07 95 1 FIPV Cerebrum 2007 NY THTRKTRRSIAD 
D04 397 1 FIPV Spleen 2004 PA TQSRRSRRSTVD 
D04 397 2 FIPV Mesenteric lymph node 2004 PA TQSRRSRRLTSN 
D04 93 1 FIPV Kidney 2004 PA THLRRSHRSTSE 
D04 93 2 FIPV Cerebrum 2004 PA TLTGRSHRSTSE 
151643 1 FIPV Heart 2008 NY TQFRRARRSAVR 
151643 2 FIPV Spleen 2008 NY TQFRRSRRSTPG 
151643 3 FIPV Liver 2008 NY TQFRRSRRSTVR 
234 t1 FECV Feces 2008 PA THTRRSRRSAPV 
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Technical Appendix Table 2. Primers used for reverse transcription PCR amplification of the feline coronavirus spike protein S1/S2 
region to detect mutation in feline coronavirus 
Primer Nucleotide sequence (5′ 3′) 
FFPE Fwd2 GCACAAGCAGCTGTGATTA 
FFPE Rev2 homology GTAATAGAATTGTGGCAT 
442(F) GGCAGAGATGGATCTATTTTTGTTA 
Sero1rev2a(R) ATAATCATCATCAACAGTGCC 
 
Technical Appendix Table 3. Fluorogenic peptides used in the furin cleavage assay to detect genetic mutation in feline coronavirus* 
Peptide Amino acid sequence 
Canonical THTRRSRRSAPA 
P1′ S-L THTRRSRRLAPA 
P1 R-G THTRRSRGSAPA 
P1 R-M THTRRSRMSAPA 
P1 R-T THTRRSRTSAPA 
P2 R-H THTRRSHRSAPA 
P2 R-L THTRRSLRSAPA 
P2 R-P THTRRSPRSAPA 
P2 R-S THTRRSSRSAPA 
P3 S-A THTRRARRSAPA 
P4 R-K THTRKSRRSAPA 
P4 R-S THTRSSRRSAPA 
P5 R-K THTKRSRRSAPA 
P6 T-F THFRRSRRSAPA 
P7 H-Q TQTRRSRRSAPA 
P7 H-Q P5 R-K TQTKRSRRSAPA 
*All peptides contain a methylcoumarin acetamido/2,4-Dinitrophenyl 
fluorescence resonance energy transfer  pair. 
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Technical Appendix Table 4.  European Nucleotide Archive accession numbers for submitted sequences of feline coronavirus spike 
protein S1/S2 junction site  
Cat-sample no. Sequence Accession no. 
106 TQSRRSRRSYPD HF954926 
110 TQTRRSRRSTSE HF954927 
111 THSRRARRSTVE HF954928 
125 TQSRRARRSQFE HF954929 
126 TQSRRSRRSASS HF954930 
128 THSRRARRSTVE HF954931 
129 TQSRRSRRSTSD HF954932 
131 TQSRRSRRSASN HF954933 
132 TQSRRSRRSAPE HF954934 
135 TQSRRARRSLPA HF954935 
136 TQSRRSRRSVVE HF954936 
137 TSSRRSRRSTPE HF954937 
138 TQSRRSRRSVAE HF954938 
140 TQSRRSRRSVVE HF954939 
141 TQSRRSRRSVVE HF954940 
142 THSRRARRSTVE HF954941 
143 TSSRRARRSSVE HF954942 
144 TQSRRSRRSASM HF954943 
146 THSRRARRSTVE HF954944 
149 TSSRRSRRSTPE HF954945 
150 TSSRRSRRSTTE HF954946 
152 THSRRSRRSNSD HF954947 
153 PHSRRSRRSTNY HF954948 
155 THSGRSRRSASD HF954949 
167 THSKRSRRSTSN HF954950 
D06 327-1 THSRRSRGSAPN HF954951 
D06 327-2 THSRRSRGSAPN HF954952 
D06 244-1 TQSRRASTSTSN HF954953 
D06 244-2 TQSRRASTSTSN HF954954 
D05 77-1 THSRRSRMSTQN HF954955 
D05 77-2 THSRRSLRSTQN HF954956 
07 129308-1 TSSRRSPRSTLD HF954957 
08 153990-1 TQPRRARMSVPE HF954958 
08 153990-2 TQPRRAPMSVPE HF954959 
08 153990-3 TQPRRARMSVPE HF954960 
08 153990-4 TQPRRARMSVPE HF954961 
N05 48-1 TQSRSSRRSTSD HF954962 
N05 110-1 TQTKRSRRSTPQ HF954963 
N05 110-2 TQTKRSRRSTPA HF954964 
N07 95-1 THTRKTRRSIAD HF954965 
D04 397-1 TQSRRSRRSTVD HF954966 
D04 397-2 TQSRRSRRLTSN HF954967 
D04 93-1 THLRRSHRSTSE HF954968 
D04 93-2 TLTGRSHRSTSE HF954969 
151643-1 TQFRRARRSAVR HF954970 
151643-2 TQFRRSRRSTPG HF954971 
234-t1 THTRRSRRSAPV HF954972 
234-t2 THTRRSLRSAPV HF954973 
304-t1 THTRRSRRSAPV HF954974 
304-t2 THTRRARRSAPV HF954975 
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Technical Appendix Figure 1. Multiple sequence alignment of regions of FECV and FIPV spike 
sequenced in this study. Complete nucleotide sequences were translated and aligned by using Geneious 
version RG (Biomatters Ltd). Logo y-axis bars indicate the sequence conservation at each site, 
expressed in bits. A consensus, sequence logo, identity histogram, and alignment are displayed for the 
FECV and FIPV datasets. The primer annealing regions are boxed. There is moderate to high 
conservation of the consensus sequence outside of a hypervariable region, which spans from position 
782 to position 802. It is within this hypervariable region that the conserved FECV furin motif 
RS/ARRS is found. 
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Technical Appendix Figure 2. Feline furin can proteolytically process PCSK9, a 
known substrate of human furin. Human HEK-293T, and feline cell lines AK-D, 
CRFK, and FCWF-4 were transfected with the wild-type (wt) mouse (m), wt human 
(h) and a human mutant form of PCSK9 (RRRR218EL) containing a furin canonical 
cleavage site, enabling complete cleavage by furin. All constructs contain a C-terminal 
V-5 tag. After undergoing proteolytic processing by several proteases, including furin, 
PCSK9 is secreted in the extracellular compartment. Twenty-four hours post-
transfection, the supernatant of transfected cells were harvested and subjected to 
Western blot analysis and detection by using mouse monoclonal anti-V5 antibodies. 
The ~55 kDa (N2) band of the protein corresponds to the furin-cleaved form of 
PCSK9. 
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CHAPTER THREE 
 
Genotypic Characterization of Canine Coronaviruses  
Associated with Fatal Canine Neonatal Enteritis in the United States 
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characterization of canine coronaviruses associated with fatal canine neonatal enteritis 
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3.1 Abstract 
Emerging canine coronavirus (CCoV) variants that are associated with systemic 
infections have been reported in the European Union; however, CCoV-associated 
disease in the United States is incompletely characterized. The purpose of this study 
was to correlate the clinicopathological findings and viral antigen distribution with the 
genotypic characteristics of CCoV in 11 puppies from nine premises in five States that 
were submitted for diagnostic investigation at Cornell University between 2008 and 
2013. CCoV antigen was found in epithelial cells of small intestinal villi in all puppies 
and the colon in two of the 10 puppies where colon specimens were available. No 
evidence of systemic CCoV infection was found. Comparative sequence analyses of 
viral RNA extracted from intestinal tissues revealed CCoV-II genotype in nine out of 
11 puppies. Of the nine CCoV-IIs, five were subtyped as group IIa, one as IIb, while 
three CCoVs could not be subtyped. One of the CCoV-IIa was isolated in cell culture. 
Infection with CCoV alone was found in five puppies, of which two also had small 
intestinal intussusception. Concurrent infections either with parvovirus (n=1), 
attaching-effacing Escherichia coli (n=4) or protozoan parasites (n=3) were found in 
the other six puppies. CCoV is an important differential diagnosis in outbreaks of 
severe enterocolitis amongst puppies between 4 days and 21 weeks of age that are 
housed in high population density. These findings will assist with rapid laboratory 
diagnosis of enteritis in puppies and highlight the need for continued surveillance for 
CCoV variants and intestinal viral diseases of global significance. 
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3.2 Introduction 
Canine coronavirus (CCoV) was first recognized a pathogen of dogs in 1971 (1) and 
together with transmissible gastroenteritis virus (TGEV) of swine and feline 
coronavirus (FCoV) is a member of the family Coronaviridae, subfamily 
Coronavirinae, genus Alphacoronavirus, species Alphacoronavirus-1 (2). Infection 
with CCoV is common in young dogs, particularly those housed in large groups such 
as kennels, shelters and breeding facilities (3-7). Traditionally, CCoV has been 
reported to infect the small intestinal villous absorptive epithelial cells resulting in 
mild and self-limiting diarrheal disease (8, 9). Young dogs, particularly those co-
infected with other enteropathogens including parvovirus, can develop severe and 
often fatal disease (8, 10-12). The emergence of CCoV variants that are associated 
with severe clinical disease, mortality and systemic infections of dogs has been 
reported from several countries in the European Union (EU) (13-18). Although fatal 
CCoV-associated disease without other pathogens was reported in two puppies in the 
United States in 2005, the CCoVs were not characterized (19). 
CCoVs circulate as two distinct genotypes: CCoV-I and CCoV-II, and both viruses 
can be detected in feces and tissues obtained from infected dogs by RT-PCR (7, 20). 
These genotypes can be distinguished on the basis of antigenic and genetic differences 
in the gene encoding the surface spike protein (21, 22). The viral spike protein binds to 
host cell receptor and triggers fusion of the viral and cellular membranes, making it an 
important determinant of cellular tropism and pathogenicity (23). Genotype I CCoV 
cannot be propagated in cell culture, and thus, is understudied compared to genotype II 
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CCoV that is easily adapted to cell culture conditions. A similar situation exists with 
the closely related FCoV type I viruses and is suspected to be due to differential 
receptor requirements between genotypes (24). CCoV-II viruses use aminopeptidase N 
(APN) as receptor (25), while the receptor for CCoV-I viruses has not been identified. 
CCoV-II viruses are classified into at least two subtypes, namely CCoV-IIa and 
CCoV-IIb, based on the sequence of the first 300 amino acids of the spike protein, a 
region known as the N-terminal domain (NTD). The NTD is an important determinant 
of intestinal tropism in the closely related TGEV (26, 27). Although the CCoV-IIa and 
-IIb classification is not part of the official CCoV taxonomy, these subtypes are widely 
referenced in the literature. Moreover, CCoV-IIa viruses also exist as two biotypes 
that differ in pathogenicity and tissue tropism and have an entirely CCoV-like NTD. 
Productive infection and replication of the classical CCoV-IIa biotype is restricted to 
intestinal epithelial cells. By contrast, an emergent pantropic CCoV-IIa biotype that 
can spread systemically is associated with profound leukopenia (28, 29), and has been 
detected from the tonsils, thymus, heart, lungs, liver, pancreas, mesenteric lymph 
node, spleen, kidneys, urinary bladder, muscles and brain of affected dogs by RT-PCR 
(13-18). Isolation of virus from extra-intestinal tissues has also been reported in some 
instances (13, 14, 16), but also failed in multiple other instances (18). The CCoV-IIb 
spike gene has a TGEV-like NTD (15, 30), and like TGEV, it causes enteritis in 
neonatal animals. Although it is generally restricted to the small intestine, CCoV-IIb 
RNA has been detected in extra-intestinal tissues of dogs co-infected with canine 
parvovirus (15-17) or with unknown co-morbidity (18). Finally, a third CCoV-II 
variant with a CCoV-I NTD has been reported in both the United States and Sweden 
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(25, 31). 
The purpose of the present study was to characterize the genotype of CCoV associated 
with outbreaks of fatal disease in young dogs submitted to the Animal Health 
Diagnostic Center (AHDC) at Cornell University between 2008 and 2013. Following 
localization of CCoV antigen in tissue sections by using immunostaining, the type and 
subtype of each virus was determined by sequencing of the NTD from purified viral 
RNA amplified by RT-PCR assay. Since changes in the proteolytic cleavage of the 
spike protein can modulate viral pathogenesis in FCoV (32), we also characterized the 
sequence of the spike protein cleavage motifs. Lastly, we used phylogenetic analysis 
to compare the sequences of the spike NTD obtained in the present study with those 
previously reported in the EU. The results of our study will assist with rapid laboratory 
diagnosis of CCoV-associated enteritis in dogs and enhance surveillance for emerging 
intestinal viral variants of global significance. 
3.3 Methods and Materials 
Diagnostic Investigation. The sample population consisted of dogs submitted to the 
AHDC at Cornell University between 2008 and 2013 with lesions of viral enteritis that 
were positive for the presence of CCoV antigen by immunohistochemical (IHC) 
staining. With the exception of puppies 4a and 4b in which selected tissues were 
collected by the referring veterinarian during a field necropsy, all cases were 
processed for complete necropsy including collection of multiple segments of 
gastrointestinal tract. In addition to gross and histopathological examinations of a 
standard set of tissues, bacteriological culture of intestinal specimens including 
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Salmonella and Campylobacter species and fluorescent antibody (FA) tests on fresh 
frozen tissue sections for CCoV, group A rotavirus and canine parvovirus were 
performed on all cases. At the request of the referring veterinarians, fresh tissues 
obtained from puppies 2, 4a, 4b and 8 were also processed for virus isolation. Dogs 
with respiratory signs or lesions were examined for the presence of canine distemper 
virus, canine parainfluenza and canine adenovirus by FA staining of frozen tissue 
sections. 
Histopathology. Sections of brain, thymus, heart, trachea, lungs, liver, gall bladder, 
tongue, stomach, pancreas, small and large intestines, mesenteric lymph node, spleen, 
kidneys, adrenal glands, urinary bladder, skeletal muscles and bone marrow were 
fixed in 10% neutral buffered formalin, embedded in paraffin, sectioned at 4-μm 
thickness, and stained with hematoxylin and eosin. Selected sections of intestinal tract 
also were stained with tissue Gram stain and a modified Steiner silver stain to further 
characterize bacteria when present. For IHC staining, sections of tissues were 
deparaffinized and processed for antigen retrieval. After blocking endogenous 
peroxidase activity with 3% hydrogen peroxide and treatment with normal goat or 
normal rabbit serum for 5 minutes (Invitrogen, Carlsbad, CA), the slides were reacted 
with the coronavirus- specific mouse monoclonal antibody FIPV3-70 (Custom 
Monoclonals International, Sacramento, CA, USA) followed by biotinylated goat anti-
mouse, streptavidin-peroxidase conjugate (Invitrogen), chromogen, 3,3-
diaminobenzidine-tetra hydrochloride and hematoxylin counterstain. Duplicate 
intestinal sections from each puppy were stained with the group A rotavirus-specific 
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mouse monoclonal antibody 9-10 (33) and canine parvovirus-specific rabbit 
polyclonal antibody CPV vp1/vp2 (Colin Parrish, Baker Institute, Cornell University). 
For FIPV3-70 and 9-10 antibodies, heat antigen retrieval consisted of microwave in 
citrate buffer at pH 6.0 for 20 minutes, whereas for CPV vp1/vp2 antibody, antigen 
retrieval was accomplished by digestion with pronase for 30 minutes. 
Virus Isolation. Ten percent tissue pools of lung, liver, spleen and intestine from 
puppy 2, intestine from puppy 4a, lung and intestine from puppy 4b, and lung, liver, 
spleen, kidney and brain from puppy 8 were prepared in Eagle minimal essential 
medium (MEM-E) containing 0.5% bovine serum albumin and 10 μg/mL 
ciprofloxacin. After tissue disruption and low speed centrifugation, 1 mL of the 
filtered supernatants from puppy 2, 4a and 4b were inoculated onto monolayers of 
canine fibroblast-like A-72 cells (ATCC CRL-1542) and immortalized canine kidney 
cells (AHDC, Cornell University), while supernatant from puppy 8 was inoculated 
onto immortalized canine kidney cells and human colorectal adenocarcinoma HRT-18 
(ATCC CCL-244) cells grown in 25-cm2 flasks as previously described (34). 
Supernatants from puppy 4a and 4b also were inoculated onto canine kidney MDCK 
cells (ATCC CCL-34) and HRT-18 cells, respectively. The extract was allowed to 
remain on the monolayer for 1–2 h and then rinsed off with phosphate buffered saline 
(PBS). Cells were cultured at 37°C in MEM-E containing 10% gamma-irradiated fetal 
bovine serum. At 5-7 day intervals, monolayers were disrupted with trypsin and new 
monolayers established at a 1:3 split ratio. Cultures were monitored on a daily basis 
for the presence of cytopathic effect. CCoV isolation was confirmed by FA staining 
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with the mouse monoclonal antibody FIPV3-70. 
RT-PCR and Genotyping. RNA was extracted from formalin-fixed and paraffin-
embedded (FFPE) tissues with RecoverAllTM Total Nucleic Acid Isolation Kit 
according to the manufacturer’s instructions (Ambion, Foster City, CA, USA). The 
resulting RNA was reverse transcribed into cDNA using SuperScriptTM III First-
Strand Synthesis System for RT-PCR (Life Technologies, Carlsbad, CA, USA). The 
RT reaction was primed with random hexamers. The presence of coronavirus cDNA 
within the sample was confirmed as previously described by PCR directed at a 
conserved region of the 3’ UTR (35). Samples that tested positive for the presence of 
coronavirus RNA based on the 3’ UTR were further characterized as genotype I or II 
using oligonucleotide primers directed against S1/S2 and S2’ cleavage motifs (Fig. 1 
and Table 1). Type II viruses were further characterized into subtypes on the basis of 
the NTD (Fig. 1 and Table 1). Previous studies on CCoV differentiate type I and type 
II CCoVs based on the sequence of the membrane (M) protein; however, it is unclear 
how changes in the M protein correlate with changes in the S protein. Therefore, we 
designed oligonucleotide primers against regions of the S protein that differ 
substantially between genotypes (Fig. 3.1 and Table 3.1). PCR was performed using 
Platinum Taq DNA Polymerase (Invitrogen Life Technologies, Carlsbad, CA, USA) 
according to the manufacturers’ instructions with an annealing temperature of 55°C. 
PCR products were analyzed by electrophoresis on a 0.8% agarose gel. Products of the 
expected size were purified using the QIAquick Gel Extraction Kit (Qiagen, Valencia, 
CA, USA). 
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Figure 3.1 CCoV-I and CCoV-II spike genes with the location of N-terminal domain 
(NTD), S1 receptor binding domain, S1/S2 cleavage site (S1/S2), S2’ cleavage site 
(S2’), S2 fusion domain and transmembrane domain (TM). Note that the S1/S2 furin 
cleavage site is only present in CCoV-I viruses.   
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Table 3.1 Oligonucleotide primers for amplification and sequencing of the 3’ UTR, 
spike N- terminal domain (NTD), spike S1/S2 cleavage site (S1/S2) and spike S2’ 
cleavage site (S2’) 
Name Specificity Sense Sequence (5’ to 3’) 
 
Product Size (base 
pairs) 
 
CCV 1-1 
  
Type 1 S1/S2 cleavage 
site 
+ CTGCTCAAGCTGCTGTAATT 244 
  - TACTACTGTGTTGGTGGTGA 
CCV 1-2 Type 1 S2’ cleavage site 
+ ATGTAATGACAGAAGTACA 261 
 - TACATTGCCATCTTATTATCA 
CCV 2-1 Type 2 S1/S2 cleavage site 
+ GCCATAGTTGGAGCTATGAC  
203 
 
- CCTATTTACAAAGAATGGCC 
CCV 2-2 Type 2 S2’ cleavage site 
+ ATGCCATTGTAATATTGTGC 225 
 - CCATCAGAATGTGTGACGTTA 
CCV-IIa IIa NTD 
+ ATGATTGTGATCGTAACTTG  
200 
 
- TTGTACCACACCTCTGTAGG 
CCV-IIb IIb NTD 
+ GAACTATAGGCAACCATTGG  
138 
  
- TACAATGCTTTAAGATTTTC 
20179a 
Type I NTD 
+ GGCTCTATCACATAACTCAGTCCTAG 163 
  CCV-IIc - TACATACTAGCTTCAAATC 
aPreviously described oligonucleotide (20) 
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Comparative Sequence Analysis. The products of the RT-PCR assays were 
sequenced by using Sanger di-deoxy sequencing method (Biotechnology Resource 
Facility, Cornell University). The CCoV RNA extracted from clinical samples was 
classified as CCoV-I or CCoV-II based on RT- PCR and sequencing of the spike 
S1/S2 and S2’ cleavage sites. Sequencing was also used to distinguish CCoV-IIa and 
CCoV-IIb variants by using a combination of new and previously published spike-
specific primers targeting the NTD (20). Oligonucleotides specific for CCoV-I NTD 
were also included in order to detect CCoV-I/CCoV-II recombinants (Fig. 1 and Table 
1). We sequenced and aligned the CCoV-II S2’ cleavage site, which is adjacent to the 
conserved coronavirus fusion peptide (36), to look for deviations from the CCoV-II 
consensus cleavage motif: K-R-K-Y-R-S, where K is the amino acid lysine, R is the 
amino acid arginine, Y is the amino acid tyrosine, and S is the amino acid serine. This 
amino acid motif is likely to be cleaved by a variety of trypsin- and cathepsin-like 
proteases, with cleavage occurring between the R and S residues. Comparative 
analysis of PCR amplified CCoV gene-specific sequences was performed on the N-
terminus of the S gene using Clustal X (Conway Institute, UCD Dublin, Ireland) and 
viewed in Genious v6.1.7 (Biomatters Ltd., Auckland, New Zealand). Neighbor- 
joining trees were constructed in Clustal X using 10,000 bootstrap trials and viewed in 
FigTree v1.4.0 (Institute of Evolutionary Biology, Edinburgh, UK). The partial 
nucleotide sequences of CCoV spike genes have been deposited in the European 
Nucleotide Archive under the accession numbers LN624642 to LN624663. 
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3.4 Results 
Clinical Findings. The signalments and clinical presentations of 11 dogs from 9 
premises investigated in the present study are presented in Table 3.2. No sex or breed 
predilections were noted. Affected puppies ranged in age from 4 days to 21 weeks 
with a median age of 7 weeks, and multiple puppies per litter and multiple litters were 
affected on most premises. The puppies were mostly housed in large groups that 
experienced severe clinical signs of intestinal illness and mortality in Indiana (n=1), 
Kansas (n=4), New York (n=4), Pennsylvania (n=1), and a litter in transit between 
shelters located in North Carolina and Rhode Island (n=1). 
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Table 3.2  Clinical history of puppies with canine coronavirus enteritis in this study 
 
Case IDa Location Breed Age Description and/or clinical sign(s) 
1 08-149076 NY Golden 
retriever 
3 weeks Breeder with 24 adults not affected; litter 
of 5 puppies with weakness, dehydration, 
vomiting, and diarrhea (2 died, 1 
recovered); in other litters, 3 puppies were 
affected (1 died, 2 recovered) 
2 09-89334 PA Yorkshire 
terrier 
21 
weeks 
Central nervous system signs, including 
hypoglycemia; a littermate with diarrhea 
died 4 days earlier 
3 09-97736 ID Spaniel 5 weeks Breeder with 15–20 adults not affected; 
puppy with 4-day history of vomiting and 
diarrhea died during surgery for jejunoileal 
intussusception; 1 littermate with 
intussusception and 2 others ill 
4a 09-107207 KS Maltese 8 weeks Distributor with 800 puppies with history 
of respiratory signs, vomiting, and diarrhea 
4b 09-110089  Basset 
hound 
8 weeks  
5 09-123567 NY Mixed 7 weeks Breeding/research facility; puppies with 
pale mucous membranes, depression, 
dehydration 
6a 10-51534A KS Bichon frise 8 weeks Breeder with 200 adults not affected; 100 
puppies with 20% mortality when 6 to 8 
weeks old 
6b 10-51534B  Mixed 8 weeks 1 to multiple puppies per litter died within 
3–4 days of showing anorexia, vomiting, 
and diarrhea 
7 12-120628 RI Mixed 5 weeks 8 rescued weaned puppies in transit from 
NC; 4 died with weakness, lethargy, 
dehydration, hypothermia 
8 12-159396 NY Shepherd 
mixed 
2 weeks Rescue bitch from KY; 5 puppies died 
from a litter of 8 
9 13-47387 NY German 
shepherd 
4 days Breeding/boarding facility with 8 adults 
showing mild vomiting and diarrhea; 2 
puppies died when 3 and 4 days old from a 
litter of 8 with abdominal pain and bloody 
stools 
  ↵a ID, identifier code. 
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Laboratory Findings. The results of IHC staining of formalin-fixed and paraffin-
embedded (FFPE) intestinal tissue sections for the presence of CCoV and other 
pathological, microbiological and parasitological findings in dogs investigated in this 
study are presented in Table 3.3. All puppies had lesions consistent with viral enteritis 
characterized by various degrees of atrophy of small intestinal villi (villous:crypt ratio 
approximately 1:2) that were lined with attenuated, low cuboidal to squamous 
epithelial cells (Fig. 3.2A). Immunostaining confirmed the presence of CCoV antigen 
within the cytoplasm of small intestinal villous epithelial cells in all of the puppies 
(Table 3.3 and Fig. 3.2B and 3.2C). Infection with CCoV extended from the 
villus:crypt junction to the tip of villi diffusely along the small intestine in puppies 5, 
7, 8, and 9, multifocally in groups of epithelial cells in puppies 1, 3, 4a, 4b, and 6b, 
and within scattered individual epithelial cells in puppies 2 and 6a. Of the 10 puppies 
in which colonic sections were available, only puppies 8 and 9 showed CCoV antigen 
within epithelial cells along the surface and crypts of the colon. Although lymphoid 
depletion of Peyer’s patches was present in 7 puppies, none of 10 puppies where 
lymphoid tissues were examined by IHC showed positive staining for the presence of 
CCoV antigen. Rare individual CCoV antigen positive cells, most likely antigen 
presenting dendritic cells, were scattered within the mesenteric lymph nodes in 
puppies 6a, 6b, and 9. None of the puppies were positive for the presence of group A 
rotavirus by FA and IHC staining or Salmonella and Campylobacter species by 
bacteriological culture of intestinal specimens. However, concurrent intestinal 
pathogens were present in six puppies. Puppy 4a had severe acute multifocal crypt 
epithelial cell necrosis that was associated with canine parvovirus antigen as 
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determined by FA and IHC staining. None of the other 10 puppies were positive for 
the presence of canine parvovirus antigen by FA and IHC staining. In addition to 
diffuse attenuation of villous epithelial cells, sections of small intestines from puppies 
2 and 5 also showed multifocal epithelial cell necrosis and sloughing into the lumen 
that was respectively associated with large and moderate numbers of cytoplasmic 
coccidian parasites. Parasitological examination of fecal samples confirmed the 
presence of Isospora species and Cystoisospora ohioensis in puppies 2 and 5, 
respectively. The small intestine of puppy 2, a young Yorkshire Terrier also showed 
multifocal crypt ectasia, a finding associated with protein-losing enteropathy in this 
breed of dogs (37). The lumen of many colonic crypts in puppy 4b contained small 
numbers of pale eosinophilic, pear-shaped flagellated protozoan parasites consistent 
with mild trichomoniasis. Closely adherent Gram negative coccobacilli consistent with 
attaching-effacing Escherichia coli (AEEC) were present multifocally along the apical 
membrane of villous epithelial cells in sections of small intestines from four puppies; 
large numbers of bacteria were present in puppy 4a, while puppies 5, 6a and 6b had 
small numbers of adherent bacteria (38). Bacteriological culture of segments of 
jejunum taken from puppies 6a and 6b yielded E. coli isolates that were typed as O 
untypable:H49 and O8:H14, respectively (E. coli Reference Center, The Pennsylvania 
State University). The isolate from puppy 6b also was positive for the presence of 
stxII, encoding Shiga-like toxin type II, and isolates from puppies 6a and 6b were 
negative for the presence of eae, encoding intimin-gamma. Consistent with clinical 
signs of weakness and vomiting, aspiration pneumonia was present in puppies 2, 5, 6a, 
and 7. Other lesions including bronchopneumonia in puppies 4b and 6b and 
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hepatocellular necrosis in puppies 8 and 9 were considered incidental findings. With 
the exception of puppy 4a where lung tissue was not available, none of the lung 
sections taken from the remaining 10 puppies were positive for the presence of CCoV 
antigen by IHC staining. 
Table 3.3 
Results of IHC staining of tissues for the presence of CCoV antigen and other findings 
in puppies investigated in this studya 
 
Cas
e 
ID CCoV IHC Other finding(s) 
SI LI Other tissues 
1 09-149076 Pos. Neg. Neg.: lung, kidney, bone 
marrow 
Peyer's patch lymphoid depletion 
2 09-89334 Pos. Neg. Neg.: lung, urinary bladder Protein-losing enteropathy, Isospora 
species, Peyer's patch lymphoid depletion, 
aspiration pneumonia 
3 09-97736 Pos. Neg. Neg.: lung, liver Jejunoileal intussusception, Peyer's patch 
lymphoid depletion 
4a 09-107207 Pos. NA NA Canine parvovirus enteritis, AEEC 
4b 09-110089 Pos. Neg. Neg.: lung, MLN Trichomoniasis, Peyer's patch lymphoid 
depletion, bronchointerstitial pneumonia 
5 09-123567 Pos. Neg. Neg.: thymus, heart, trachea, 
lung, liver, pancreas, spleen 
AEEC, Cystoisospora ohioensis, aspiration 
pneumonia 
6a 10-51534A Pos. Neg. Pos.: MLN (rare); Neg.: 
thymus, lung, stomach, 
pancreas 
AEEC, aspiration pneumonia, bone marrow 
depletion, thymic and MLN lymphoid 
depletion 
6b 10-51534B Pos. Neg. Pos.: MLN (rare); Neg.: 
thymus, lung 
AEEC, bronchopneumonia, bone marrow 
depletion, thymic, MLN and Peyer's patch 
lymphoid depletion 
7 12-120628 Pos. Neg. Neg.: lung, tongue, stomach, 
MLN, liver, gallbladder, 
pancreas, kidney 
Jejunojejunal intussusception, ulcerative 
gastritis, Peyer's patch lymphoid depletion, 
aspiration pneumonia 
8 12-159396 Pos. Pos. Neg.: thymus, lung, liver, 
stomach, spleen, kidney 
Mild, multifocal, acute hepatocellular 
necrosis 
9 13-47387 Pos. Pos. Pos.: MLN (rare); Neg.: lung, 
stomach 
Peyer's patch lymphoid depletion, mild, 
multifocal, subacute hepatocellular necrosis ↵a SI, small intestine; LI, large intestine; Pos., positive; Neg., negative; NA, not 
available; MLN, mesenteric lymph node; AEEC, attaching-effacing Escherichia coli. 
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Figure 3.2 Photomicrographs of small intestine from puppy 8 with typical lesions of 
CCoV infection. (A) The villus epithelial cells are diffusely disorganized, attenuated, 
and low cuboidal (arrows). Note that the space between the epithelial cells and the 
lamina propria is an artifact of processing (hematoxylin and eosin stain; bar, 100  m). 
(B) Cross-section of small intestine showing CCoV antigen in villus epithelial cells 
(arrows; immunohistochemical stain; bar, 500 μm). (C) Higher magnification showing 
CCoV antigen in the cytoplasm of villus epithelial cells (arrows; 
immunohistochemical stain; bar, 50 μm).  
 
 
Virus Isolation. CCoV was isolated from puppy 4b and canine parvovirus was 
isolated from puppy 4a. CCoV cytopathic effect (CPE) consisting of cell rounding, 
cell death and syncytia formation was observed 24 hours post-inoculation of canine A-
72 cells (Fig. 3.3A and 3.3B). The other two cell lines did not yield CCoV. Infected 
A-72 cells were positive for the presence of CCoV antigen by FA staining (Fig. 3.3C). 
Sequencing of CCoV RNA extracted from infected cell culture lysates further 
confirmed infection of puppy 4b with CCoV-IIa that corresponded to the RT-PCR 
assay and sequencing results from corresponding FFPE intestinal specimen. 
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Figure 3.3 Canine fibroblast-like A-72 cells, 24 hours post-infection with puppy 4b 
CCoV. Phase contrast microscopy of uninfected cell culture monolayer (A) and CCoV-
infected cell culture monolayer with cytopathic effect characterized by rounding and 
death of individual cells (B) (10X original magnification). Immunofluorescence 
microscopy of CCoV-infected cell culture monolayer (mouse monoclonal antibody 
FIPV3-70 followed by Alexa Fluor 488 conjugated anti-IgG; 20X original 
magnification). 
 
 
 
RT-PCR, Genotyping and Comparative Sequence Analysis. Coronavirus RNA was 
detected by RT-PCR in nine out of 11 puppies; sufficient CCoV RNA was not 
recovered from puppy 1 and 6b (Table 4). Comparative sequence analysis revealed 
CCoV-II in all 9 cases. Consequently, the S1/S2 cleavage site was not analyzed 
because it is only present in CCoV-I genotype (Fig. 3.1) (39). The CCoVs from 
puppies 3, 4b, 5, 7 and 8 were subtyped as CCoV-IIa, while the CCoV from puppy 9 
was subtyped as CCoV-IIb, and those from puppies 2, 4a, and 6a could not be 
subtyped. The S2’ site was sequenced in eight out of the nine puppies from which 
CCoV RNA was successfully extracted. No variations in amino acid sequence at the 
cleavage site were detected (Table 3.4). Based on a neighbor-joining phylogenic tree 
of available CCoV NTDs (National Center for Biotechnology Information; 
http://www.ncbi.nlm.nih.gov/), CCoV-IIa viruses from puppies 3, 4b, 5, 7 and 8 
clustered with other CCV-IIa viruses, including those associated with previous reports 
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of pantropic CCoV in the EU, while the CCoV-IIb from puppy 9 clustered with 
CCoV-IIb from the EU (Fig. 3.4). 
 
Figure 3.4 Phylogenetic tree based on the spike protein N-terminal domain (NTD). 
Sequences are identified as CCoV-IIa or -IIb followed by the case number. 
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Table 3.4 Results of NTD genotyping and S2’ subtyping of canine coronaviruses 
(CCoV) in this study. Genotyping and subtyping of reference CCoV-I and –II are 
included.   
 
CCoV (case) Genotype Subtype S2’ Cleavage 
Site Sequence 
S1/S2 Cleavage  
Site Sequence 
89334-09 (2) II ND KRKYRS ARTR  - - - - -  G 
97736-09 (3) II a KRKYRS ERTR  - - - - -  G 
107207 (4a) II ND KRKYRS DRTR  - - - - -  G 
110089-09 (4b) II a KRKYRS ARTR  - - - - -  G 
123567-09 (5) II a KRKYRS ERTR  - - - - -  G 
51534-10A (6a) II ND KRKYRS ARTR  - - - - -  G 
120628-12 (7) II a KRKYRS ND 
159396-12 (8) II a KRKYRS ERTR  - - - - -  G 
47387-13 (9) II b KRKYRS ARTR  - - - - -  G 
Reference CCoV  
CB/05 II a KRKYRS ARTR  - - - - -  G 
1-71 II a KRKYRS ERTR  - - - - -  G 
341/05 II b KRKYRS ARTR  - - - - -  G 
Elmo/02 I  QPGGRS VRRARRAVQG 
 
The reference CCoV-IIa pantropic CB/05 (AAZ91437.1), CCoV-IIa “enteric” 1-71 
(AAV65515.1), CCoV-IIb 341/05 (ACJ63231.1) and CCoV-I Elmo/02 (AAP72149) 
are included to highlight the conserved nature of the S2’ cleavage site within genotype 
II viruses. Basic residues suspected to be important for cleavage activation of the spike 
protein are in bold. ND, not determined. 
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3.5  Discussion  
Although closely related to pantropic CCoV-IIa, the CCoV-IIa associated with 
neonatal mortality in our study were restricted to the intestinal tract, and therefore, 
consistent with classical enteric CCoV infection (19, 40). The use of immunostaining 
to confirm CCoV disease in our study might explain the lack of detection of pantropic 
CCoV. Previous work on pantropic CCoV has relied mainly on RT-PCR to detect 
systemic spread. RT-PCR is very sensitive and can detect viral genome in tissues 
without productive viral replication or infection being present. IHC is arguably a better 
method for detecting clinically relevant infection because it requires high levels of 
viral antigen, and therefore viral replication, to yield a positive result. In addition, IHC 
can localize antigen to biologically relevant cellular compartments such as the 
cytoplasm of infected villous epithelial cells (Fig. 3.2B and 3.2C). Because detection 
of viral antigen by immunostaining is highly time dependent, early infection with 
concentrations of CCoV antigen below the detection limit of the assay cannot be ruled 
out completely as a reason for the lack of detection of CCoV in extra-intestinal tissues 
of our puppies. Confirmation of pantropic CCoV in previous reports relied primarily 
on RT-PCR assays; however, whether viral replication or infection is present in 
individual tissues cannot be conclusively confirmed by this method alone. Conversely, 
isolation of CCoV viruses from extra-intestinal tissues has been reported, but the 
clinical significance of this finding is unclear without co-localization of extra-
intestinal lesions with viral antigen. Previous reports with FCoV have confirmed viral 
RNA by RT-PCR in tissues obtained from otherwise healthy cats (41). As with CCoV, 
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immunostaining is generally negative in these cases. In the same studies, the positive 
RT-PCR results were attributed to viremia, a finding that is common among cats 
experiencing asymptomatic enteric infection with FCoV (42). The possibility that 
viremia may be associated with low-level virus replication within tissues of healthy 
animals cannot be ruled out completely (41). 
Viral tropism was found to extend to the large intestines in puppies 8 and 9, 
respectively infected with CCoV-IIa and CCoV-IIb. To our knowledge, colonic 
infection has only been documented in one of five experimentally-infected 10-week-
old puppies, 10 days post- inoculation with the C54 reference CCoV-II (40, 43). Given 
that concurrent pathogens were not found, extensive intestinal infection with CCoV 
alone most likely accounted for the demise of puppies 8 and 9. In support of this 
interpretation was the presence of hepatocellular necrosis in these puppies; a common 
finding in animals with extensive loss of intestinal barrier integrity which results in 
showering of the portal circulation by toxic products. Interestingly, these were the 
youngest puppies (4 days and 2 weeks), and host factors such as age may have 
contributed to CCoV infection of colonic epithelial cells. 
Lymphopenia is a common clinical finding in reports of dogs with pantropic CCoV 
infection. Although hemograms were not available, lymphoid depletion of the thymus, 
mesenteric lymph nodes or intestinal Peyer’s patches was present in eight out of 10 
puppies that had lymphoid tissues available. Similar lymphoid depletion was found in 
two puppies with fatal CCoV-associated enteritis previously described in the United 
States (19). Consistent with the previous report, CCoV infection of lymphoid tissues 
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was not found in our study. Infections with other coronaviruses including Middle 
Eastern Respiratory Syndrome (MERS) coronavirus, severe acute respiratory 
syndrome (SARS) coronavirus, equine coronavirus (ECoV), and FCoV are associated 
with lymphopenia (44-47). Where the cause of lymphopenia has been investigated, it 
is attributed to indirect mechanisms secondary to the viral infection such as cytokine-
mediated apoptosis (48, 49). 
All but one of the puppies in our study originated from high-density housing where 
outbreaks of enterocolitis were ongoing. Over half (6/11 or 54%) of our cases had 
concurrent intestinal infections with various combinations of pathogens. Co-infection 
with canine parvovirus, a known risk factor for CCoV associated mortality, was found 
in only puppy 4a. Severe intestinal damage can result in translocation of toxic 
products to extra-intestinal tissues, particularly the lungs and liver. Consistent with 
this observation, bronchopneumonia and hepatocellular necrosis were present in four 
puppies. Additionally, aspiration pneumonia, a common clinical complication seen in 
young debilitated puppies that are vomiting was also present in four puppies. The 
clinical significance of intestinal infection with AEEC in four puppies is unclear; 
however, the presence of small intestinal epithelial colonization by these organisms 
likely contributed to clinical signs of intestinal dysfunction leading to mortality in 
these cases. Clearly, host and environmental factors such overcrowding of puppies, 
co-infections with intestinal pathogens, pathogen load and degree of maternal 
immunity can determine the outcome of CCoV-associated enteritis. Although 
mutations in the S2’ cleavage site were not found, it remains possible that unidentified 
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viral factors also could have contributed to the fatal outcomes. These factors may 
include variations in the NTD, a region that is known to be important for 
enterotropism in TGEV. Subtyping of CCoV-II was based on the amino acid sequence 
of the NTD (Fig. 1). Because both CCoV-IIa and -IIb viruses were associated with 
fatal outcomes, it appears that viruses with a CCoV-like NTD (subtype CCoV-IIa) or a 
TGEV-like NTD (CCoV-IIb) have the potential to cause fatal enteritis. 
Intussusception was observed in the small intestine of two of the 11 puppies with fatal 
CCoV-associated enteritis (Table 3.3). Interestingly, puppy 3 was from a breeding 
facility where a littermate with small intestinal intussusception recovered following 
surgical resection and anastomosis. This breeder recalled having over a dozen other 
puppies with small intestinal intussusception over the last two years following the 
introduction of several breeders acquired from Sweden where CCoV outbreaks were 
documented around the same period (31). Interestingly, a similar association between 
CCoV infection and small intestinal intussusception was reported in one of the two 
puppies previously described in the United States (19). The pathogenesis of intestinal 
intussusception associated with enteric viral infection is not well understood; however, 
in human infants, intestinal intussusception has been associated with adenovirus and 
enterovirus infections as well as vaccination with a discontinued live-attenuated 
rhesus-human reassortant rotavirus tetravalent vaccine (50-52). The observation that 
CCoV- associated enteritis can sometime present with small intestinal intussusception 
suggests a similar pathogenesis.  Our study provides detailed pathological findings in 
11 puppies with fatal CCoV- associated enteritis that originated from nine premises in 
  98 
five States in the United States between 2008 and 2013. Key regions of the viral spike 
gene were sequenced to determine if viral factors played a role in these CCoV-
associated mortalities. Owing to the retrospective nature of the present study with 
available FFPE tissue samples collected at necropsy with variance in post- mortem 
intervals, sample quality and degree of RNA crosslinking by formalin fixation 
combined with the relatively low ratio of viral to cellular RNA within tissues and the 
natural variability of CCoV S gene limited our ability to use next generation 
sequencing methods to capture a more complete assessment of the viral populations 
involved in these cases. Another limitation of the present study was our inability to 
subtype the CCoV-II viruses from three puppies which was likely attributable to 
divergent NTD that could not be amplified by our PCR primers. Lastly, approximately 
50% prevalence of CCoV-I and CCoV-II co-infections has been reported previously; 
however, we were unable to detect any CCoV-I infections in our study. Our CCoV-I 
primers were based on multiple alignments of previously published CCoV-I virus 
sequences in the region of the S1/S2 and S2’ cleavage sites. It is possible that the 
puppies in our study were infected with divergent CCoV-I viruses that were not 
amplified by our S-specific primers. 
This study revealed the presence of CCoV-IIb variants in the United States and 
highlighted the potential of CCoV-IIa and IIb to cause morbidity and mortality in 
puppies. Extended tissue tropism of CCoV to the large intestine was found in two 
puppies; however, pantropic CCoV infections were not identified. Isolation of CCoV-
IIa from puppy 4b confirmed the validity of genotyping results obtain
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corresponding FFPE tissue sections. CCoVs should be considered as a differential 
diagnosis and specifically sought in outbreaks of severe enteritis among puppies up to 
21 weeks of age particularly when housed in high population density, but also in cases 
with small intestinal intussusception or enteritis associated with infections caused 
either by parvovirus, AEEC or protozoan parasites. 
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